

US009187783B2

(12) United States Patent

Esfandyarpour et al.

(10) Patent No.:

US 9,187,783 B2

(45) **Date of Patent:**

*Nov. 17, 2015

(54) SYSTEMS AND METHODS FOR AUTOMATED REUSABLE PARALLEL BIOLOGICAL REACTIONS

(75) Inventors: Hesaam Esfandyarpour, Los Altos, CA

(US); Mark F. Oldham, Emerald Hills, CA (US); Eric S. Nordman, Palo Alto, CA (US); Kosar Baghbani Parizi, Los

Altos, CA (US)

(73) Assignee: GENAPSYS, INC., Redwood City, CA

(US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-

claimer.

(21) Appl. No.: 13/824,129

(22) PCT Filed: Oct. 4, 2011

(86) PCT No.: PCT/US2011/054769

§ 371 (c)(1),

(2), (4) Date: **Nov. 4, 2013**

(87) PCT Pub. No.: WO2012/047889

PCT Pub. Date: Apr. 12, 2012

(65) **Prior Publication Data**

US 2014/0045701 A1 Feb. 13, 2014

Related U.S. Application Data

- (60) Provisional application No. 61/389,490, filed on Oct. 4, 2010, provisional application No. 61/389,484, filed on Oct. 4, 2010, provisional application No. 61/443,167, filed on Feb. 15, 2011, provisional application No. 61/491,081, filed on May 27, 2011.
- (51) **Int. Cl.** *C12Q 1/68* (2006.01) *G01N 27/414* (2006.01)

(58) Field of Classification Search

None

See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

5,602,042 A	2/1997	Farber
5,612,181 A	3/1997	Fourmentin-Guilbert
5,795,782 A	8/1998	Church et al.
5,834,197 A	11/1998	Parton
6,046,097 A	4/2000	Hsieh et al.
6,087,095 A	7/2000	Rosenthal et al.
6,210,891 B1	4/2001	Nyren et al.

6,327,410	B1	12/2001	Walt et al.
6,632,655	B1	10/2003	Mehta et al.
6,833,246	B2	12/2004	Balasubramanian
6,953,958	B2	10/2005	Baxter et al.
7,081,192	B1	7/2006	Wang et al.
7,223,540	B2	5/2007	Pourmand et al.
7,242,241	B2	7/2007	Toumazou et al.
7,270,981	B2	9/2007	Armes et al.
7,282,370	B2	10/2007	Bridgham et al.
7,291,496	B2	11/2007	Holm-Kennedy
7,312,085	B2	12/2007	Chou et al.
7,317,216	B2	1/2008	Holm-Kennedy
7,361,466	B2	4/2008	Korlach et al.
7,399,590	B2	7/2008	Piepenburg et al.
7,435,561	B2	10/2008	Piepenburg et al.
7,485,428	B2	2/2009	Armes et al.
7,615,382	B2	11/2009	Wang et al.
7,645,596	B2	1/2010	Williams et al.
7,649,358	B2	1/2010	Toumazou et al.
7,666,598	B2	2/2010	Piepenburg et al.
7,682,837	B2	3/2010	Jain et al.
7,686,929	B2	3/2010	Toumazou et al.
7,692,219	B1	4/2010	Holm-Kennedy
7,695,907	B2	4/2010	Miyahara et al.
		(Cont	tinued)
		· COII	imucu i

FOREIGN PATENT DOCUMENTS

CN 1337580 A 2/2002 CN 101120098 A 2/2008 (Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 13/397,581, filed Feb. 15, 2012, Esfandyarpour et al. (Continued)

Primary Examiner — Juliet Switzer
Assistant Examiner — Sahana Kaup
(74) Attorney, Agent, or Firm — Wilson Sonsini Goodrich &
Rosati

(57) ABSTRACT

A method comprises magnetically holding a bead carrying biological material (e.g., nucleic acid, which may be in the form of DNA fragments or amplified DNA) in a specific location of a substrate, and applying an electric field local to the bead to isolate the biological material or products or byproducts of reactions of the biological material. For example, the bead is isolated from other beads having associated biological material. The electric field in various embodiments concentrates reagents for an amplification or sequencing reaction, and/or concentrates and isolates detectable reaction by-products. For example, by isolating nucleic acids around individual beads, the electric field can allow for clonal amplification, as an alternative to emulsion PCR. In other embodiments, the electric field isolates a nanosensor proximate to the bead, to facilitate detection of at least one of local pH change, local conductivity change, local charge concentration change and local heat. The beads may be trapped in the form of an array of localized magnetic field regions.

US 9,187,783 B2Page 2

U.S. PATENT DOCUMENTS 2010/03/2576 AJ 27201 Williams et al. 7.634.437 BJ 27010 Pipepalwage et al. 2011/03/256 AJ 57201 Pipepalwage et al. 2011/03/256 AJ 72011 Pipepalwage et al. 2011/03/256 AJ 72011 Edandyapyour et al. 2011/03/256 AJ 82011 Edandyapyour et al. 2011/03/256 AJ 92011 Edandyapyour et al. 2011/03/256 AJ 92011 Edandyapyour et al. 2011/03/256 AJ 92011 Edandyapyour et al. 2011/03/256 AJ 92012 Edandyapyour et al. 2011/03/256 AJ	(56)	Referer	nces Cited	2010/0317531			Balasubramanian et al.
7.763.427 B2 7.2010 Pipepahung et al. 2011/01/2059 A1 5.2011 Themps et al. 7.875.449 B2 1.2011 Williams et al. 2011/01/2059 A1 5.2011 Hoser of al. 7.875.449 B2 1.2011 Williams et al. 2011/01/2059 A1 5.2011 Hoser of al. 7.875.449 B2 1.2011 Williams et al. 2011/01/2059 A1 5.2011 Hoser of al. 7.875.449 B2 1.2011 Williams et al. 2011/01/2059 A1 7.2011 Williams et al. 2011/01/2059 A1 7.2011 Williams et al. 2011/01/2059 A1 8.2011 Himz et al. 8.606.285 B2 11.2011 Pipepahung et al. 2011/01/2059 A1 8.2011 Himz et al. 8.606.285 B2 11.2011 Pipepahung et al. 2011/01/2059 A1 8.2011 Himz et al. 8.606.285 B2 11.2011 Pipepahung et al. 2011/01/2059 A1 8.2011 Himz et al. 8.606.285 B2 11.2011 Pipepahung et al. 2011/01/2059 A1 8.2011 Himz et al. 8.606.285 B2 11.2011 Pipepahung et al. 2011/01/2059 A1 8.2011 Ribare et al. 2011/01/2059 A1 8.2011 Himz et al. 8.606.285 B2 11.2011 Pipepahung et al. 2011/01/2059 A1 8.2011 Ribare et al. 2011/01/2059	II S	DATENIT	DOCUMENTS				
7.763.427 B2 7.2010 Pipepahung et al. 2011/01/18139 A1 52011 Mehis et al. 1 1 1 1 1 1 1 1 1	0.3.	PALENT	DOCOMENTS				
7.834,890 B2 112010 loser et al. 20110123991 A1 5.2011 Hoser 1.0	7.763.427 B2	7/2010	Piepenburg et al.				
7.938.013 B2 2.2011 Mynhama et al. 7.932.014 B2 4.2011 Estandayapour et al. 7.932.014 B2 4.2011 Estandayapour et al. 7.932.016 B2 5.2011 Robberg et al. 8.030.000 B2 10.2011 Perpenburg et al. 8.042.830 B2 11.2011 Goldstein et al. 8.042.830 B2 11.2011 Goldstein et al. 8.042.830 B2 11.2011 Perpenburg et al. 8.114.99 B2 2.2012 Tounazour et al. 8.114.99 B2 2.2012 Tounazour et al. 8.114.99 B2 2.2012 Tounazour et al. 8.112.91 B2 3.2012 Weindel et al. 8.127.90 B2 3.2012 Weindel et al. 8.127.90 B2 3.2012 Weindel et al. 8.127.90 B2 3.2012 Perpenburg et al. 8.127.90 B2 3.2012 Perpenburg et al. 8.127.90 B2 4.2012 Briman et al. 8.2010.000 B2 3.2012 Perpenburg et al. 8.2010.000 B2 3.2015 Perpenburg et al. 8.20							
7.93.2034 B2 42011 Isfandyarpour et al. 7.94.015 B2 5.2011 Rottberg et al. 8.060.000 B2 102011 Piepenburg et al. 8.060.284 B2 11.2011 Piepenburg et al. 8.060.285 B2 11.2011 Piepenburg et al. 8.071.308 B2 12.2011 Piepenburg et al. 8.171.308 B2 2.2012 Tournazour et al. 8.171.308 B2 2.2012 Tournazour et al. 8.171.308 B2 2.2012 Tournazour et al. 8.172.108 B2 2.2012 Tournazour et al. 8.201.109 B2 2.2012 Tourna							
2,948,015 92 5,2011 Rothberg et al. 2011/0195253 Al. 8,2011 Hinz et al. 8,062,348 82 11/2011 Goldstein et al. 2011/0201506 Al. 8,2011 Hinz et al. 8,062,348 82 11/2011 Flepenburg et al. 2011/0201506 Al. 8,2011 Hinz et al. 8,071,308 82 12/2011 Flepenburg et al. 2011/0201507 Al. 9,2011 Rothberg et al. 8,071,308 82 2,2012 Toumazou et al. 2011/02/3037 Al. 9,2011 Rothberg et al. 8,114,599 82 2,2012 Selige et al. 2011/02/48319 Al. 10/2011 Rothberg et al. 8,123,790 81 3,2012 Selige et al. 2011/02/48319 Al. 10/2011 Rothberg et al. 8,123,919 82 4,2012 Briman et al. 2011/02/8339 Al. 10/2011 Rothberg et al. 8,173,40 82 5,2012 Chang et al. 2011/02/8339 Al. 10/2011 Rothberg et al. 8,173,926 82 5,2012 Selige et al. 2011/02/8339 Al. 10/2011 Rothberg et al. 8,173,926 82 5,2012 Kelly et al. 2011/02/8745 Al. 11/2011 Rothberg et al. 8,279,325 82 9,2012 Brown et al. 2011/02/8745 Al. 11/2011 Rothberg et al. 8,408,375 82 6,2013 Goldstein et al. 2011/02/8745 Al. 11/2011 Rothberg et al. 8,408,375 82 6,2013 Goldstein et al. 2011/02/8745 Al. 11/2011 Rothberg et al. 8,575,466 82 82/13 Goldstein et al. 2011/02/8745 Al. 11/2011 Rothberg et al. 8,575,466 82 82/13 Goldstein et al. 2011/02/8745 Al. 11/2011 Rothberg et al. 8,637,356 82 32/14 Earnot et al. 2011/02/8745 Al. 11/2012 Rothberg et al. 8,637,356 82 32/14 Earnot et al. 2011/02/8745 Al. 11/2012 Rothberg et al. 8,637,356 82 32/14 Earnot et al. 2012/03/976 Al. 22/012 Rothberg et al. 8,637,356 82 32/14 Earnot et al. 2012/03/9561 Al. 22/012 Rothberg et al. 8,637,356 82 32/014 Earnot et al. 2012/03/9561 Al. 22/012 Rothberg et al. 8,637,356 82 32/014 Earnot et al. 2012/03/9561 Al. 22/012 Rothberg et al. 8,637,356 82 32/014 Earnot et al. 2							
8,030,000 B2 0.0201 Piepenburg et al. 2011/02/1056 Al. 8,2011 Hinz et al.							
8,002,348 B2 11/2011 Goldstein et al. 2011/02/1079 A1 92/011 Rothberg et al. 8,073.56 B2 11/2011 Piepenburg et al. 2011/02/1079 A1 92/011 Rothberg et al. 8,073.56 B2 12/2011 Piepenburg et al. 2011/02/1079 A1 92/011 Rothberg et al. 8,173.56 B2 22/012 Clumazou et al. 2011/02/4793 A1 10/2011 Rothberg et al. 8,173.56 B2 22/012 Ishige et al. 2011/02/4793 A1 10/2011 Rothberg et al. 8,173.56 B2 33/012 Ishige et al. 2011/02/4793 A1 10/2011 Rothberg et al. 8,173.56 B2 33/012 Ishige et al. 2011/02/4793 A1 10/2011 Rothberg et al. 8,173.56 B2 33/012 Ishige et al. 2011/02/4793 A1 10/2011 Rothberg et al. 8,173.56 B2 33/012 Ishige et al. 2011/02/4793 A1 10/2011 Rothberg et al. 8,173.56 B2 33/012 Ishige et al. 2011/02/4793 A1 10/2011 Rothberg et al. 8,173.56 B2 33/012 Ishige et al. 2011/02/4793 A1 10/2011 Rothberg et al. 8,173.56 B2 20/012 Emorre et al. 2011/02/4793 A1 10/2011 Rothberg et al. 8,173.56 B2 52/012 Kelly et al. 2011/02/4793 A1 11/2011 Rothberg et al. 8,173.56 B2 20/012 Emorre et al. 2011/02/4793 A1 11/2011 Rothberg et al. 8,173.56 B2 20/012 Emorre et al. 2011/02/4793 A1 11/2011 Rothberg et al. 2011/02/4793 A1 11/2011 Rothberg et al. 2011/03/4794 A1 11/2012 Rothberg et al. 2011/03/4794 A1 11							
Septemberg et al. 2011/0217697 Al 92011 Rothberg et al. 8/01/1308 Bz 12/2011 Pripenburg et al. 2011/0217697 Al 92011 Rothberg et al. 8/01/1308 Bz 22/012 Totumazou et al. 2011/0241881 Al 10/2011 Rothberg et al. 8/13/309 Bz 23/012 Usinge et al. 2011/0248320 Al 10/2011 Rothberg et al. 8/13/309 Bz 23/012 Usinge et al. 2011/0248320 Al 10/2011 Rothberg et al. 8/13/309 Bz 23/012 Usinge et al. 2011/0248320 Al 10/2011 Rothberg et al. 8/13/309 Bz 23/012 Usinge et al. 2011/0248320 Al 10/2011 Rothberg et al. 8/13/309 Bz 23/012 Usinge et al. 2011/0248320 Al 10/2011 Rothberg et al. 8/13/309 Bz 23/012 Usinge et al. 2011/024843 Al 10/2011 Rothberg et al. 8/13/309 Bz 23/012 Edward et al. 2011/024843 Al 10/2011 Rothberg et al. 8/13/309 Bz 23/012 Edward et al. 2011/024843 Al 10/2011 Rothberg et al. 8/13/309 Bz 23/012 Edward et al. 2011/024843 Al 10/2011 Rothberg et al. 8/13/309 Bz 23/012 Edward et al. 2011/024843 Al 10/2011 Rothberg et al. 8/13/309 Bz 23/012 Brown et al. 2011/024843 Al 10/2011 Rothberg et al. 8/13/309 Bz 23/012 Brown et al. 2011/024843 Al 11/2011 Rothberg et al. 2011/024843 Al 11/2011 Rothber				2011/0201506	A1	8/2011	Hinz et al.
Section							
S.128.796 B2 3/2012 Salige et al. 2011/02/48319 Al 0/2011 Rothberg et al. 8,129.198 B2 4/2012 Briman et al. 2011/02/48319 Al 10/2011 Rothberg et al. 8,152.998 B2 4/2012 Briman et al. 2011/02/48320 Al 10/2011 Rothberg et al. 8,152.996 B2 5/2012 Chang et al. 2011/02/6863 Al 10/2011 Rothberg et al. 8,179.206 B2 5/2012 Chang et al. 2011/02/6863 Al 10/2011 Rothberg et al. 8,179.206 B2 5/2012 Chang et al. 2011/02/6863 Al 10/2011 Rothberg et al. 2011/02/6864 Al 10/2012 Rothberg et al. 2012/00/3390 Al 12/2012 Rothberg et al. 2012/00/34007 Al 22/2012 Rothberg et al. 2012/00/3401 Al 12/2004 Rother et al. 2012/00/3841 Al 12/2004 Rother et al. 2012/00/3841 Al 12/2004 Rother et al. 2012/00/3841 Al 12/2004 Rother et al. 2012/00/38682 Al 12/2004 Rother et al. 2012/00/38682 Al 12/2004 Rother et al. 2012/00/3868 Al 2012/00/38682 Al 12/2004 Rother et al. 2012/00/3868 Al 2	, ,						
8,129,118 32 3/2012 Weinfield et al. 2011/02/48320 Al. 10/2011 Rothberg et al. 8,157,590 32 3/2012 Brimac et al. 2011/02/8930 Al. 10/2011 Rothberg et al. 8,173,401 BZ 5/2012 Chang et al. 2011/02/8930 Al. 10/2011 Dobhinger et al. 8,173,401 BZ 5/2012 Chang et al. 2011/02/8934 Al. 10/2011 Rothberg et al. 8,173,401 BZ 5/2012 Chang et al. 2011/02/8743 Al. 11/2011 Wong et al. 8,275,725 BZ 9/2012 Brown et al. 2011/02/8743 Al. 11/2011 Wong et al. 8,450,487 BZ 6/2013 Armes et al. 2011/02/8745 Al. 11/2011 Rothberg et al. 8,450,487 BZ 6/2013 Armes et al. 2011/02/8745 Al. 12/2011 Rothberg et al. 8,551,486 BZ 11/2013 Piepenburg et al. 2011/02/8115 Al. 12/2011 Rothberg et al. 8,585,677 BZ 11/2013 Piepenburg et al. 2012/00/34607 Al. 22/2012 Rothberg et al. 8,585,273 BZ 11/2013 Piepenburg et al. 2012/00/34607 Al. 22/2012 Rothberg et al. 8,585,273 BZ 11/2013 Piepenburg et al. 2012/00/34607 Al. 22/2012 Rothberg et al. 2012/00/35811 Al. 22/2012 Rothberg et al. 2012/00/35811 Al. 22/2014 Rothberg et al. 2012/00/35811 Al. 22/2012 Rothberg et al. 2012/00/3581 Al. 22/2012 Rothberg et al. 2012/00/35811 Al. 22/2012 Rothberg et al. 2012/00/35813 Al. 22/2012 Rothber							
8,137,569 B2 3/2012 Briman et al. 2011/0259745 A1 102011 Rothberg et al. 8,173,401 B2 5/2012 Chang et al. 2011/0263463 A1 102011 Rothberg et al. 8,173,401 B2 5/2012 Chang et al. 2011/0263463 A1 102011 Rothberg et al. 8,179,206 B2 5/2012 Kelly et al. 2011/0287945 A1 112011 Working et al. 8,476,134 B2 4/2013 Prepenburg et al. 2011/0287945 A1 112011 Working et al. 8,406,873 B2 6/2013 Armses et al. 2011/0287945 A1 112011 Working et al. 8,456,134 B2 4/2013 Prepenburg et al. 2011/0287945 A1 112011 Working et al. 8,578,4846 B2 112013 Prepenburg et al. 2012/0013302 A1 12012 Rothberg et al. 8,578,4846 B2 112013 Prepenburg et al. 2012/0013302 A1 12012 Rothberg et al. 8,578,4846 B2 112013 Prepenburg et al. 2012/0034067 A1 22012 Rothberg et al. 8,578,573 B2 112013 Esfandyarpour et al. 2012/0046844 A1 22012 Rothberg et al. 8,578,573 B2 112013 Esfandyarpour et al. 2012/0046844 A1 22012 Rothberg et al. 8,673,550 B2 3/2014 Learnon et al. 2012/0045841 A1 22012 Rothberg et al. 2012/0046844 A1 22012 Rothberg et al. 2012/0046844 A1 22012 Rothberg et al. 2012/0046934 A1 12005 Choong et al. 2012/0061555 A1 3/2012 Rothberg et al. 2012/0061555 A1 3/2012 Rothberg et al. 2012/00610373 A1 12004 Kin et al. 2012/0061255 A1 3/2012 Rothberg et al. 2005/00109784 A1 1/2005 Su et al. 2012/0061255 A1 3/2012 Rothberg et al. 2005/00109784 A1 1/2005 Su et al. 2012/0061255 A1 3/2012 Rothberg et al. 2006/0002884 A1 1/2006 Rothberg et al. 2012/0061255 A1 3/2012 Rothberg et al. 2006/00105373 A1 5/2006 Pourmand et al. 2012/0061255 A1 3/2012 Rothberg et al. 2006/00105373 A1 5/2006 Pourmand et al. 2012/0061256 A1 3/2012 Rothberg et al. 2006/00105373 A1 5/2006 Rothberg et al. 2012/0071340 A1 6/2007 Bradley et al. 2012/0071340 A1 6/2007 Bradley et al. 2012/0071340 A1 6/2007 Bradley et al. 2012/0071340 A1 8/2007 Work et al. 2012/0071340 A1 8/2007 Rothberg et al. 2012/0071340 A1 1/2003 Rothberg et al. 2012							Ç
S. 15.2.99 B2 4.2012 Briman et al. 2011/0267463 Al 10.2011 Robbinger et al. S. 17.3.001 Robbinger et al. 2011/0267463 Al 10.2011 Robbinger et al. 2011/0267463 Al 12.2011 Robbinger et al. 2011/0267463 Al 12.2012 Robbinger et al. 2011/0267463 Al 12.2012 Robbinger et al. 2011/0267463 Al 12.2012 Robbinger et al. 2011/0267463 Al 2012 Robbinger et al. 2011/0267469 Al 2012 Robbinger et al. 2012/0267881 Al 2012 Robbinger et al. 2012/0267888 Al 2012 Robbinger et al. 2012/02678888 Al 2012 Robbinger et al. 2012/02678888 Al 2012 Robbinger et al. 2012/02678888				2011/0248320	A1	10/2011	Rothberg et al.
S.179.296 B2 \$5.2012 Kelly et al. 2011/0287945 1 11/2011 Wong et al. 8.456.735 B2 \$6.2013 Piepenburg et al. 2011/0287945 1 12/2011 Rothberg et al. 8.450.875 B2 \$6.2013 Armes et al. 2011/039197 1 12/2011 Rothberg et al. 8.546.875 B2 \$6.2013 Armes et al. 2011/031979 1 12/2011 Rothberg et al. 8.574,846 B2 11/2013 Piepenburg et al. 2012/0031807 A 2.2012 Rothberg et al. 8.585,973 B2 11/2013 Esfandyarpour 2012/0034607 A1 2.2012 Rothberg et al. 8.585,973 B2 11/2013 Esfandyarpour 2012/0034607 A1 2.2012 Rothberg et al. 8.637,560 B2 3.2014 Esfandyarpour et al. 2012/0034844 A1 2.2012 Rothberg et al. 8.969,000 B2 3.2015 Esfandyarpour et al. 2012/0034844 A1 2.2012 Rothberg et al. 2003/00209432 A1 11/2003 Choong et al. 2012/0035813 A1 3.2012 Rothberg et al. 2004/003492 A1 11/2004 Kim et al. 2012/0035813 A1 3.2012 Rothberg et al. 2004/003492 A1 11/2004 Kim et al. 2012/0055813 A1 3.2012 Rothberg et al. 2005/0009022 A1 12/2005 Welliams et al. 2012/0056813 A1 3.2012 Rothberg et al. 2005/0009022 A1 12/2005 Welliams et al. 2012/0056813 A1 3.2012 Rothberg et al. 2005/0009023 A1 2.2005 Welliams et al. 2012/0056813 A1 3.2012 Rothberg et al. 2005/0009023 A1 2.2005 Rothberg et al. 2012/0056813 A1 3.2012 Rothberg et al. 2005/0009023 A1 2.2005 Rothberg et al. 2012/005681 A1 3.2012 Rothberg et al. 2005/0009023 A1 2.2005 Rothberg et al. 2012/0056813 A1 3.2012 Rothberg et al. 2005/0009023 A1 2.2005 Rothberg et al. 2012/0056813 A1 3.2012 Rothberg et al. 2005/0009023 A1 2.2005 Rothberg et al. 2012/0056813 A1 3.2012 Rothberg et al. 2005/0009023 A1 2.2005 Rothberg et al. 2012/0056813 A1 2.2005 Rothberg et al. 2012/0056813 A1 2.2005 Rothberg et al. 2012/0056813 A1 2.2005 Rothberg et al. 2012/00							
Section Sect							
8.426,154 B2 47913 Piepenburg et al. 2011 (10294115 Al 122011 Williams et al. 8.450,875 B2 67913 Armes et al. 2011 (20013892 Al 122012 Roibberg et al. 8.518,670 B2 87913 Piepenburg et al. 2012 (2003396 Al 122012 Roibberg et al. 8.585,870 B2 11/2013 Piepenburg et al. 2012 (2003396 Al 122012 Roibberg et al. 8.585,870 B2 11/2013 Esfandyarpour 2012 (2003396 Al 122012 Roibberg et al. 8.673,550 B2 32014 Estandyarpour et al. 2012 (20045844 Al 22012 Roibberg et al. 8.673,550 B2 32014 Estandyarpour et al. 2012 (20045844 Al 22012 Roibberg et al. 8.673,550 B2 32014 Estandyarpour et al. 2012 (2005581) Al 32012 Roibberg et al. 2004 (200403424 Al 122004 Estandyarpour et al. 2012 (2005581) Al 32012 Roibberg et al. 2004 (20032042 Al 11/2003 Choong et al. 2012 (2005581) Al 32012 Roibberg et al. 2012 (20050390) Al 22005 Choong et al. 2012 (2005581) Al 32012 Roibberg et al. 2012 (20050390) Al 22005 Williams et al. 2012 (20061255 Al 32012 Roibberg et al. 2012 (20050390) Al 22005 Williams et al. 2012 (20061255 Al 32012 Roibberg et al. 2012 (20050390) Al 22005 Williams et al. 2012 (2005690) Al 32012 Roibberg et al. 2012 (2005690) Al 32013 Roibberg et al. 2012 (2005690) Al 32013 Roibberg et al. 2012 (2005690) Al 32013 Roibberg et al. 2012 (20056							
Section							
8.518,670 B2 8/2013 Goldstein et al. 2012/00/13392 Al 1/2012 Bothberg et al. 8.574,846 B2 11/2013 Piepenburg et al. 2012/00/34607 Al 2/2012 Bashir et al. 8.585,973 B2 11/2013 Piepenburg et al. 2012/00/34607 Al 2/2012 Rothberg et al. 8.585,973 B2 11/2014 Piepenburg et al. 2012/00/34607 Al 2/2012 Rothberg et al. 8.585,973 B2 11/2014 Piepenburg et al. 2012/00/34607 Al 2/2012 Rothberg et al. 8,673,255 B2 3/2015 Esfandyarpour et al. 2012/00/5811 Al 3/2012 Rothberg et al. 8,969,002 B2 3/2015 Choong et al. 2012/00/5811 Al 3/2012 Rothberg et al. 2004/00/342 Al 1/2004 Chen 2012/00/61255 Al 3/2012 Rothberg et al. 2004/00/3402 Al 1/2004 Chen 2012/00/61255 Al 3/2012 Rothberg et al. 2004/00/3402 Al 1/2004 Chen 2012/00/6125 Al 3/2012 Rothberg et al. 2005/00/00/3402 Al 1/2005 Su et al. 2012/00/6173 Al 3/2012 Rothberg et al. 2005/00/30/3402 Al 1/2005 Su et al. 2012/00/6173 Al 3/2012 Rothberg et al. 2005/00/30/3402 Al 1/2005 Su et al. 2012/00/6173 Al 3/2012 Rothberg et al. 2006/00/2084 Al 1/2006 Ronaghi et al. 2012/00/6802 Al 1/2005 Su et al. 2012/00/69/34 Al 1/2005 Ronaghi et al. 2012/00/69/34 Al 1/2006 Ronaghi et al. 2012/00/69/34 Al 1/2006 Ronaghi et al. 2012/00/69/34 Al 1/2006 Barten et al. 2012/00/69/34 Al 1/2006 Barten et al. 2012/00/69/34 Al 1/2006 Barten et al. 2012/00/37/37 Al 3/2012 Rothberg et al. 2007/01/37/37 Al 1/2008 Barten et al. 2012/00/38/34 Al 1/2008 Ronaghi et al. 2012/01/37/34 Al 4/2012 Rothberg et al. 2007/01/37/37/37 Al 1/2008 Forman et al. 2012/01/37/38 Al 3/2012 Rothberg et al. 2007/01/37/37/37 Al 1/2008 Ronaghi et al. 2012/01/37/39 Al 5/2012 Rothberg et al. 2007/01/37/37/37 Al 1/2008 Rother et al. 2012/01/37/38 Al 3/2012 Rothberg et al. 2012/01/37/3							
8.580,307 B2 11/2013 Peperburg et al. 8.585,973 B2 11/2013 Esfandyarpour 2012/00034607 A1 2/2012 Rothberg et al. 8.637,253 B2 1/2014 Peperburg et al. 2012/004844 A1 2/2012 Rothberg et al. 8.637,253 B2 1/2014 Peperburg et al. 2012/004844 A1 2/2012 Rothberg et al. 8.637,350 B2 3/2014 Peperburg et al. 2012/0058811 A1 3/2012 Rothberg et al. 2003/0209432 A1 1/2003 Esfandyarpour et al. 2012/0058811 A1 3/2012 Rothberg et al. 2004/001401 A1 1/2004 Kim et al. 2012/005002 A1 1/2003 Chen 2012/0061255 A1 3/2012 Rothberg et al. 2004/001401 A1 1/2005 Veiner et al. 2005/000902 A1 1/2005 Veiner et al. 2012/0061733 A1 3/2012 Rothberg et al. 2005/000902 A1 1/2005 Veiner et al. 2012/0061733 A1 3/2012 Rothberg et al. 2005/000902 A1 1/2005 Veiner et al. 2012/0061733 A1 3/2012 Rothberg et al. 2005/000903 A1 3/2012 Rothberg et al. 2005/000903 A1 3/2012 Rothberg et al. 2005/00093 A1 3/2012 Rothberg et al. 2006/00093 A1 3/2012 Rothberg et al. 2008/001600000000000000000000000000000000							
8.585.973 B2 11.2013 Estandyarpour 2012/0037961 A1 2.2012 Rothberg et al. 8.6373.560 B2 3.2014 Expending et al. 2012/0048844 A1 2.2012 Rothberg et al. 8.6673.560 B2 3.2014 Expending et al. 2012/0048844 A1 2.2012 Rothberg et al. 8.6673.560 B2 3.2014 Expending et al. 2012/005813 A1 3.2012 Rothberg et al. 2.004.001401 A1 1.2003 Expending et al. 2012/005813 A1 3.2012 Rothberg et al. 2.004.001401 A1 1.2004 Expending et al. 2012/0061256 A1 3.2012 Rothberg et al. 2.004.001401 A1 1.2005 Expending et al. 2012/0061256 A1 3.2012 Rothberg et al. 2.005.00103784 A1 1.2005 Weiner et al. 2012/0061256 A1 3.2012 Rothberg et al. 2.005.00103784 A1 1.2005 Weiner et al. 2012/0065093 A1 3.2012 Rothberg et al. 2.005.00103784 A1 1.2005 Weiner et al. 2012/0065093 A1 3.2012 Rothberg et al. 2.005.0010373 A1 5.2005 Weiliams et al. 435.6 2012/0058660 A1 4.2012 Rothberg et al. 2.006.010537 A1 5.2005 Purmand et al. 2012/0094871 A1 4.2012 Rothberg et al. 2.006.010537 A1 5.2005 Weiliams et al. 2012/0094871 A1 4.2012 Rothberg et al. 2.007.0137537 A1 1.2006 Purmand et al. 2012/0094871 A1 4.2012 Rothberg et al. 2.007.0137537 A1 1.2006 Purmand et al. 2012/0094871 A1 4.2012 Rothberg et al. 2.007.0137537 A1 1.2006 Purmand et al. 2012/0094871 A1 4.2012 Rothberg et al. 2.007.0137537 A1 1.2006 Purmand et al. 2012/0094871 A1 4.2012 Rothberg et al. 2.007.0137537 A1 1.2006 Purmand et al. 2012/0094871 A1 4.2012 Rothberg et al. 2.007.0137537 A1 1.2006 Rothberg et al. 2012/0094871 A1 4.2012 Rothberg et al. 2.008.0167637 A1 7.2008 Rothberg et al. 2012/0094871 A1 4.2012 Rothberg et al. 2.008.0167637 A1 7.2008 Rothberg et al. 2012/0094871 A1 4.2012 Rothberg et al. 2.008.0167637 A1 7.2008 Rothberg et al. 2012/0094871 A1 4.2012 Rothberg et al. 2.008.0167637 A1 7.2008 Rothberg et al. 2012/0094871 A							
8.637,253 B2							
8,673,560 B2 3/2015 Esfandyarpour et al. 2012/0045844 Al 2/2012 Rothberg et al. 2003/02/09432 Al 11/2003 Choong et al. 2012/005813 Al 3/2012 Rothberg et al. 2012/005/05/2013 Al 3/2012 Rothberg et al. 2012/006/205 Al 3/2012 Rothberg et al. 2012/008/205 Al 2020 Barton et al. 2012/008/205 Al 1/2006 Barton et al. 2012/008/205 Al 2020 Founamou et al. 2012/012/373 Al 5/2012 Rothberg et al. 2008/016/205 Al 2020 Founamou et al. 2012/012/373 Al 5/2012 Rothberg et al. 2008/016/207 Al 7/2008 Founamou et al. 2012/012/373 Al 5/2012 Rothberg et al. 2008/016/207 Al 7/2008 Founamou et al. 2012/012/373 Al 5/2012 Rothberg et al. 2008/016/207 Al 7/2008 Founamou et al. 2012/012/373 Al 5/2012 Rothberg et al. 2008/016/207 Al 7/2008 Bardyarpour et al. 2012/013/3870 Al 5/2012 Rothberg et al. 2008/016/207 Al 7/2008 Bardyarpour et al. 2012/013/3870 Al 5/2012 Rothberg et al. 2008/016/37 Al 7/2008 Rotherg et al. 2012/013/3870 Al 5/2012 Rothberg et al. 2012/013/3870 Al							
S.969,002 B2 32015 Esfandyarpour et al. 20012005SR1 A1 32012 Rothberg et al. 2004001420 A1 12004 Kim et al. 20120061255 A1 32012 Rothberg et al. 20040061349 A1 22004 Chen 20120061255 A1 32012 Rothberg et al. 20040061349 A1 22005 Williams et al. 20120061255 A1 32012 Rothberg et al. 20050019784 A1 12005 Sut al. 20050019784 A1 12005 Williams et al. 43516 2012006601373 A1 32012 Rothberg et al. 201200601373 A1 32012 Rothberg et al. 201200601373 A1 32012 Rothberg et al. 201200601373 A1 32012 Rothberg et al. 2012006373 A1 32012 Rothberg et al. 201200707373 A1 32012 Rothberg et al. 2012003873 A1 42012 Rothberg et al. 2012003873 A1 52012 Picpenburg et al. 2012003873 A1 20200 A1 2009 A1 2000				2012/0045844	Al		
2004/0014291 A1							
2004/0033492 Al 2/2004 Cheen 2012/0061226 Al 3/2012 Rothberg et al. 2005/0019784 Al 1/2005 Weiner et al. 2012/0065093 Al 3/2012 Rothberg et al. 2005/0019784 Al 1/2005 Weiner et al. 2012/0065093 Al 3/2012 Rothberg et al. 2006/00208824 Al 1/2006 Rothberg et al. 2006/00205269 Al 1/2006 Rothberg et al. 2006/00205269 Al 1/2006 Rothberg et al. 2006/00205269 Al 1/2006 Rothberg et al. 2007/0132043 Al 6/2007 Bradley et al. 2007/0134463 Al 8/2007 Molho et al. 2007/0132043 Al 1/2007 Wan Eijk 2007/0275375 Al 1/2007 Van Eijk 2008/0032295 Al 2/2008 Tournazou et al. 2008/01202973 Al 5/2012 Rothberg et al. 2008/0113226 Al 7/2008 Tournazou et al. 2008/011323 Al 7/2008 Tournazou et al. 2008/011323 Al 7/2008 Esfandyarpour et al. 2008/013243 Al 1/2008 Markawa et al. 2008/0302732 Al 1/2008 Markawa et al. 2008/0302732 Al 1/2008 Rothberg et al. 2009/002398 Al 1/200 Rothberg et al. 2009/0032401 Al ** 2/200 Rothberg et al. 2009/003							
2005/0009032							
2005/0019784 A.1 1/2005 Su et al. 2012/0056093 A.1 3/2012 Rothberg et al. 2006/0008824 A.1 1/2006 Rothage et al. 2012/00791363 A.1 3/2012 Rothberg et al. 2012/0079085660 A.1 4/2012 Rothberg et al. 2012/0079085660 A.1 4/2012 Rothberg et al. 2012/0079085662 A.1 4/2012 Rothberg et al. 2012/0079085662 A.1 4/2012 Rothberg et al. 2012/0079073 A.1 5/2012 Rothberg et al. 2007/0075375 A.1 1/2007 Van Fijk 2012/0129728 A.1 5/2012 Rothberg et al. 2012/0129730 A.1 5/2012 Rothberg et al. 2008/0162074 A.1 7/2008 Tournazou et al. 2012/0129732 A.1 5/2012 Rothberg et al. 2008/0162074 A.1 7/2008 Erandyarpour et al. 2012/0138803 A.1 5/2012 Rothberg et al. 2008/016677 A.1 7/2008 Brown et al. 2012/0138803 A.1 5/2012 Dramana et al. 2012/0183803 A.1 5/2012 Dramana et al.						3/2012	Rothberg et al.
2005/0032076 A1* 2/2005 Williams et al. 435/6 2012/0071633 A1 3/2012 Rothberg et al. 2006/00105373 A1 5/2006 Pournand et al. 2012/0088660 A1 4/2012 Rothberg et al. 2006/0105373 A1 5/2006 Pournand et al. 2012/0094871 A1 4/2012 Hinze et al. 2012/01094871 A1 4/2012 Hinze et al. 2012/01094871 A1 5/2012 Rothberg et al. 2007/0123043 A1 6/2007 Bardiey et al. 2012/012973 A1 5/2012 Rothberg et al. 2007/0123755 A1 11/2007 Van Eijk 2012/012973 A1 5/2012 Rothberg et al. 2008/0161200 A1 7/2008 Tournazou et al. 2012/012973 A1 5/2012 Rothberg et al. 2008/016120 A1 7/2008 Tournazou et al. 2012/012973 A1 5/2012 Rothberg et al. 2008/016120 A1 7/2008 Fafandyarpour et al. 2012/012973 A1 5/2012 Rothberg et al. 2008/0166727 A1 7/2008 Esfandyarpour et al. 2012/0135870 A1 5/2012 Rothberg et al. 2008/0176817 A1 7/2008 Brown et al. 2012/0135870 A1 5/2012 Rothberg et al. 2008/0176817 A1 7/2008 Brown et al. 2012/0135870 A1 5/2012 Rothberg et al. 2008/0176817 A1 7/2008 Brown et al. 2012/0135870 A1 7/2012 Dormanac et al. 2008/0318243 A1 12/2008 Murakawa et al. 2012/0156728 A1 6/2012 Bagbhani-Parizi et al. 2008/0318243 A1 12/2008 Rothberg et al. 2012/0225496 A1 9/2012 Davey et al. 2009/002935 A1 12/2009 Rothberg et al. 2012/0258456 A1 10/2012 Marnigonians 2009/002935 A1 12/2009 Rothberg et al. 2012/0225496 A1 9/2012 Marnigonians 2009/0029340 1A1* 2/2009 Rothberg et al. 2012/0205819 A1 11/2012 Erlander et al. 2009/0127589 A1 5/2009 Rothberg et al. 2012/0205819 A1 11/2012 Erlander et al. 2009/0127580 A1 7/2009 Balasubramanian et al. 2012/0205819 A1 11/2012 Erlander et al. 2009/0127580 A1 7/2009 Balasubramanian et al. 2013/00304880 A1 1/2011 Learnon et al. 2019/0103552 A1 2/2010 Rothberg et al. 2013/0039760 A1 3/2012 Erlander et al. 2010/0073055 A1 4/2010 Gibtes et al. 2013/0095076 A1 3/2013 Learnon et al. 2010/013743 A1 6/2010 Rothberg et al. 2013/0095076 A1 3/2013 Erlander et al. 2010/013743 A1 6/2010 Rothberg et al. 2013/0095076 A1 3/2013 Erlander et al. 2010/015788 A1 7/2010 Rothberg et al. 2010/015788 A1 7/2010 Rothberg et al. 2010/015788						3/2012	Rothberg et al.
2006/0105373 Al 5/2006 Pourmand et al. 2012/0058682 Al 4/2012 Rothberg et al. 2006/0105373 Al 5/2012 Piepenburg et al. 2012/010594871 Al 2012/012703 Al 5/2012 Piepenburg et al. 2007/0154463 Al 8/2007 Molho et al. 2012/012973 Al 5/2012 Rothberg et al. 2007/015375 Al 1/2007 Van Eijk 2012/012973 Al 5/2012 Rothberg et al. 2008/016375 Al 1/2007 Al 2012/012973 Al 5/2012 Rothberg et al. 2008/016320 Al 7/2008 Tournazou et al. 2012/0125870 Al 5/2012 Rothberg et al. 2008/0166727 Al 7/2008 Fishandyarpour et al. 2012/0135870 Al 5/2012 Rothberg et al. 2008/0166727 Al 7/2008 Brown et al. 2012/0135870 Al 5/2012 Rothberg et al. 2008/0166727 Al 7/2008 Brown et al. 2012/0135870 Al 5/2012 Baghbaii-Parizi et al. 2008/016817 Al 7/2008 Brown et al. 2012/0156728 Al 6/2012 Li et al. 2008/0302732 Al 10/2008 Murakawa et al. 2012/0156728 Al 6/2012 Davey et al. 2008/0302732 Al 12/2008 Haga et al. 2012/0175159 Al 7/2012 Tournazou et al. 2009/0026082 Al 1/2009 Haga et al. 2012/0258496 Al 10/2012 Mamigonians 2009/0026082 Al 1/2009 Rothberg et al. 2012/0258496 Al 10/2012 Piepenburg et al. 2009/0032401 Al * 2/2009 Ronaghi et al. 2012/0258496 Al 10/2012 Piepenburg et al. 2009/017589 Al 5/2009 Ronaghi et al. 2012/02058499 Al 10/2012 Piepenburg et al. 2009/017693 Al 7/2009 Ronaghi et al. 2012/0302454 Al 11/2012 Eafandyarpour et al. 2009/01076021 Al 7/2009 Ronaghi et al. 2012/0302454 Al 11/2012 Eafandyarpour et al. 2013/00350252 Al 7/2009 Ronaghi et al. 2013/0035093 Al 1/2013 Leamon et al. 2010/0035252 Al 2/2010 Rothberg et al. 2013/0059080 Al 4/2013 Eafandyarpour et al. 2010/0137413 Al 6/2010 Rothberg et al. 2013/0059080 Al 4/2013 Eafandyarpour et al. 2010/0153946 Al 7/2009 Granas et al. 2010/0153946 Al 7							
2006/0222569 Al 10/2006 Barten et al. 2012/0094871 Al 4/2012 Hinz et al. 2012/012973 Al 5/2012 Frepenburg et al. 2012/012973 Al 5/2012 Rothberg et al. 2007/0132043 Al 2/2008 Al 2/2009 Al 2/2008 Al 2/2009 Al 2/2008 Al 2/2009 Al 2/2008 Al 2/2008 Al 2/2008 Al 2/2008 Al 2/2009 Al 2/2008 Al 2/2009 Al 2/2008							
2007/0132-043							
2007/0184463 Al 8/2007 Van Eijk 2012/0129703 Al 5/2012 Rothberg et al.							
2008/0032295 Al 7/2008 Yournazou et al. 2012/0129732 Al 5/2012 Rothberg et al. 2008/016727 Al 7/2008 Yu et al. 2012/0135870 Al 5/2012 Drmanac et al. 2008/0166727 Al 7/2008 Fafandyarpour et al. 2012/0138460 Al 6/2012 Baghbani-Parizi et al. 2008/0176817 Al 7/2008 Zhou et al. 2012/0137159 Al 7/2012 Davey et al. 2008/0302732 Al 12/2008 Soh et al. 2012/0175252 Al 7/2012 Davey et al. 2008/0302733 Al 12/2008 Soh et al. 2012/0175252 Al 7/2012 Davey et al. 2009/00281824 Al 12/2008 Fafandyarpour et al. 2012/0175252 Al 7/2012 Davey et al. 2009/0029385 Al 1/2009 Rothberg et al. 2012/0258496 Al 01/2012 Armse et al. 2009/0029385 Al 1/2009 Christians et al. 2012/0258496 Al 01/2012 Piepenburg et al. 2009/0029385 Al 1/2009 Leamon et al. 2012/0258499 Al 10/2012 Pietiti 2009/0166221 Al 7/2009 Leamon et al. 2012/0303444 Al 11/2012 Esfandyarpour et al. 2009/0175789 Al 5/2009 Rothberg et al. 2012/03034454 Al 11/2012 Esfandyarpour et al. 2009/0181385 Al 7/2009 Balasubramanian et al. 2013/0025013 Al 1/2013 Esfandyarpour et al. 2009/0181385 Al 7/2009 Rothberg et al. 2013/0032011 Al 1/2013 Leamon et al. 2010/0073525 Al 7/2009 Rothberg et al. 2013/0034880 Al 2/2013 Clamon et al. 2010/0073835 Al 4/2010 Oliver 2013/00359762 Al 3/2013 Leamon et al. 2010/0137413 Al 6/2010 Rothberg et al. 2013/00359762 Al 3/2013 Leamon et al. 2010/0137413 Al 6/2010 Rothberg et al. 2013/025421 Al 8/2013 Esfandyarpour et al. 2010/0137413 Al 6/2010 Rothberg et al. 2013/025421 Al 8/2013 Esfandyarpour et al. 2010/015344 Al 7/2010 Rothberg et al. 2013/0235437 Al 2/2013 Esfandyarpour et al. 2010/015344 Al 7/2010 Rothberg et al. 2013/0235437 Al 2/2014 Esfandyarpour et al. 2010/015344 Al 7/2010 Rothberg et al. 2011/013743 Al 6/2010 Rothberg et al. 2011/013743 Al 6/2010 Rothberg et al. 2011/0137454 Al							
2008/0161200 A1 7/2008 Yu et al. 2012/0135870 A1 5/2012 Commance et al. 2008/0166727 A1 7/2008 Esfandyarpour et al. 2012/01358870 A1 5/2012 Baghbani-Parizi et al. 2008/0171325 A1 7/2008 Zhou et al. 2012/0138460 A1 6/2012 Baghbani-Parizi et al. 2008/0302732 A1 1/2008 Zhou et al. 2012/0135873 A1 7/2012 Zhou et al. 2008/0302732 A1 1/2008 Zhou et al. 2012/0175252 A1 7/2012 Zhou et al. 2008/0318243 A1 1/2008 Zhou et al. 2012/01252496 A1 9/2012 Zhou et al. 2009/002385 A1 1/2009 Rothberg et al. 2012/0258498 A1 10/2012 Peipenburg et al. 2009/0032401 A1 * 2/2009 Ronaghi et al. 2012/0258499 A1 10/2012 Peipenburg et al. 2009/0127589 A1 5/2009 Rothberg et al. 2012/0258499 A1 10/2012 Peipenburg et al. 2009/0127589 A1 5/2009 Rothberg et al. 2012/0295819 A1 11/2012 Leamon et al. 2009/0107024 A1 7/2009 Ishige et al. 2013/002341 A1 1/2012 Esfandyarpour et al. 2009/010724 A1 7/2009 Ishige et al. 2013/0023011 A1 1/2012 Erfander et al. 2013/0035929 A1 3/2013 Leamon et al. 2013/0035929 A1 3/2013 Leamon et al. 2013/003988 A1 2/2010 Rothberg et al. 2013/0059290 A1 3/2013 Armes et al. 2010/0013743 A1 2/2010 Rothberg et al. 2013/0096013 A1 4/2013 Sikora et al. 2010/013743 A1 2/2010 Rothberg et al. 2013/0096013 A1 4/2013 Sikora et al. 2010/015946 A1 2/2010 Rothberg et al. 2013/0096013 A1 4/2013 Sikora et al. 2010/0159461 A1 2/2010 Rothberg et al. 2013/0096013 A1 4/2013 Sikora et al. 2010/0159461 A1 2/2010 Rothberg et al. 2013/0096013 A1 4/2013 Sikora et al. 2010/0159461 A1 2/2010 Rothberg et al. 2013/0096013 A1 4/2014 Esfandyarpour et al. 2010/0163414 A1 7/2010 Rothberg et al. 2010/016345							
2008/0166727 Al							
2008/0171325 Al 7/2008 Brown et al. 2012/0158460 Al 6/2012 Ei et al. 2008/0176817 Al 7/2008 Zhou et al. 2012/0173159 Al 7/2012 Davey et al. 2008/0302732 Al 10/2008 Murakawa et al. 2012/0175159 Al 7/2012 Davey et al. 2008/0318243 Al 12/2008 Soh et al. 2012/0175252 Al 7/2012 Toumazou et al. 2009/0026082 Al 1/2009 Rothberg et al. 2012/0258456 Al 10/2012 Armes et al. 2009/0023855 Al 1/2009 Christians et al. 2012/0258456 Al 10/2012 Petitit 2009/0023401 Al * 2/2009 Ronaghi et al. 2012/0258499 Al 10/2012 Petitit 2009/0023401 Al * 2/2009 Ronaghi et al. 2012/0258499 Al 10/2012 Petitit 2009/0048124 Al 2/2009 Ronaghi et al. 2012/03024617 Al 11/2012 Leamon et al. 2009/0127589 Al 5/2009 Rothberg et al. 2012/0302454 Al 11/2012 Esfandyarpour et al. 2009/016221 Al 7/2009 Balasubramanian et al. 2012/0302454 Al 11/2012 Esfandyarpour et al. 2009/01870724 Al 7/2009 Balasubramanian et al. 2013/0003613 Al 1/2013 Leamon et al. 2009/0191594 Al 7/2009 McKernan et al. 2013/0034880 Al 2/2013 Oldham 2010/0078325 Al 4/2010 Rothberg et al. 2013/0034880 Al 2/2013 Oldham 2010/0078325 Al 4/2010 Oliver 2013/009606 Al 4/2013 Sikora et al. 2010/0137413 Al 6/2010 Rothberg et al. 2013/00259762 Al 3/2013 Eamon et al. 2010/0137413 Al 6/2010 Rothberg et al. 2013/0231254 Al 9/2013 Sikora et al. 2010/0159461 Al 6/2010 Rothberg et al. 2013/0231254 Al 9/2013 Esfandyarpour et al. 2010/0159461 Al 6/2010 Rothberg et al. 2013/023413 Al 2/2013 Esfandyarpour et al. 2010/0163414 Al 7/2010 Sikora et al. 2013/0234313 Al 3/2014 Esfandyarpour et al. 2010/0163414 Al 7/2010 Sikora et al. 2013/0234313 Al 3/2014 Esfandyarpour et al. 2010/0163414 Al 7/2010 Sikora et al. 2011/0107333 Al 2/2014 Esfandyarpour et al. 2010/0163414 Al 7/2010 Sikora et al. 2011/01073334 Al 2/2014 Esfandyarpour et al. 2010/016							
2008/031841 Al 10/2008 Murakawa et al. 2012/0173159 Al 7/2012 Tournazou et al. 2008/0302732 Al 12/2008 Soh et al. 2012/0175252 Al 7/2012 Tournazou et al. 2008/0318243 Al 12/2008 Rothberg et al. 2012/0225496 Al 10/2012 Armes et al. 2009/0026082 Al 1/2009 Rothberg et al. 2012/0258456 Al 10/2012 Armes et al. 2009/002385 Al 1/2009 Rothberg et al. 2012/0258499 Al 10/2012 Peipenburg et al. 2009/0032401 Al * 2/2009 Ronaghi et al. 2012/0264617 Al 10/2012 Peipenburg et al. 2009/0127589 Al 5/2009 Ronaghi et al. 2012/0302454 Al 11/2012 Leamon et al. 2012/0302454 Al 11/2012 Esfandyarpour et al. 2009/016621 Al 7/2009 Balasubramanian et al. 2012/0302113 Al 11/2012 Erlander et al. 2009/0181385 Al 7/2009 McKernan et al. 2013/003513 Al 1/2013 Leamon et al. 2013/003525 Al 2/2010 Rothberg et al. 2013/0034880 Al 2/2013 Al 2/2014 Al 2/2010 Rothberg et al. 2013/0059290 Al 3/2013 Armes et al. 2010/0072080 Al 3/2010 Karhanek et al. 2013/009860 Al 4/2013 Erlander et al. 2013/009860 Al 4/2013 Erlander et al. 2013/0059290 Al 3/2013 Armes et al. 2010/0137413 Al 6/2010 Rothberg et al. 2013/009860 Al 4/2013 Erlander et al. 2013/005976 Al 3/2013 Erlander et al. 2013/005976 Al 3/2014 Erlander et al. 2013/005976							
2008/0302732 Al 12/2008 Soh et al. 2012/0175252 Al 7/2012 Toumazou et al. 2008/0318243 Al 12/2008 Haga et al. 2012/02258456 Al 10/2012 Armes et al. 2019/0202985 Al 1/2009 Rothberg et al. 2012/0258456 Al 10/2012 Petitit 2009/0032401 Al* 2/2009 Leamon et al. 2012/025849 Al 10/2012 Petitit 2009/0048124 Al 2/2009 Leamon et al. 2012/025849 Al 11/2012 Leamon et al. 2019/0048124 Al 11/2012 Leamon et al. 2019/004813 Al 11/2012 Leamon et al. 2019/004813 Al 11/2012 Leamon et al. 2019/004813 Al 11/2013 Leamon et al. 2019/004880 Al 2/2013 Oldham 2009/019724 Al 7/2009 McKernan et al. 2013/0034880 Al 2/2013 Oldham 2010/0035252 Al 2/2010 Rothberg et al. 2013/0059762 Al 3/2013 Armes et al. 2013/0059762 Al 3/2013 Armes et al. 2010/0072080 Al 3/2010 Karhanek et al. 2013/009860 Al 4/2013 Sikora et al. 2010/0137413 Al 6/2010 Rothberg et al. 2013/009860 Al 4/2013 Sikora et al. 2010/0137413 Al 6/2010 Rothberg et al. 2013/0231254 Al 8/2013 Lie al. 2010/0159461 Al 6/2010 Rothberg et al. 2013/0231254 Al 8/2013 Lie al. 2010/0159461 Al 6/2010 Gillies et al. 2013/0231254 Al 8/2013 Lie al. 2010/0159461 Al 6/2010 Gillies et al. 2013/0231254 Al 8/2013 Lie al. 2010/0159461 Al 6/2010 Gillies et al. 2013/0231254 Al 8/2013 Lie al. 2010/0159461 Al 6/2010 Gillies et al. 2014/0075339 Al 2/2014 Esfandyarpour et al. 2010/0169461 Al 6/2010 Gillies et al. 2014/0035359 Al 2/2014 Esfandyarpour et al. 2010/0235555 Al 0/2010 Rothberg et al. 2014/035457 Al 8/2014 Esfandyarpour et al. 2010/0235555 Al 0/2010 Rothberg et al. 2014/035457 Al 8/2014 Esfandyarpour et al. 2010/030559 Al 2/2							
2008/0318243 A1 12/2008 Haga et al. 2012/0222496 A1 9/2012 Mamigonians 2009/0020385 A1 1/2009 Rothberg et al. 2012/0258499 A1 10/2012 Prepenburg et al. 2009/0032401 A1 * 2/2009 Ronaghi et al. 2012/0258499 A1 10/2012 Prepenburg et al. 2009/0048124 A1 2/2009 Ronaghi et al. 2012/0258499 A1 11/2012 Leamon et al. 2009/0048124 A1 2/2009 Rothberg et al. 2012/0302454 A1 11/2012 Esfandyarpour et al. 2009/0127589 A1 7/2009 Rothberg et al. 2012/0302454 A1 11/2012 Esfandyarpour et al. 2009/0181385 A1 7/2009 Balasubramanian et al. 2013/0023011 A1 12/2012 Erlander et al. 2009/0191594 A1 7/2009 Ohashi 2013/0034880 A1 2/2013 Clamon et al. 2010/0035252 A1 2/2010 Rothberg et al. 2013/0059020 A1 3/2013 Armes et al. 2010/0072080 A1 3/2010 Karhanek et al. 2013/0059762 A1 2/2013 Sikora et al. 2010/0137143 A1 6/2010 Rothberg et al. 2013/0096013 A1 4/2013 Esfandyarpour et al. 2010/0137143 A1 6/2010 Rothberg et al. 2013/00906013 A1 4/2013 Esfandyarpour et al. 2010/0151479 A1 6/2010 Rothberg et al. 2013/0023011 A1 2/2013 Esfandyarpour et al. 2010/0150461 A1 6/2010 Toumazou et al. 2013/0231254 A1 9/2013 Esfandyarpour et al. 2010/0167938 A1 7/2010 Gillies et al. 2013/023137 A1 2/2014 Esfandyarpour et al. 2010/0167938 A1 7/2010 Rothberg et al. 2014/0073531 A1 3/2014 Esfandyarpour et al. 2010/0255555 A1 2/2010 Rothberg et al. 2014/00335457 A1 8/2014 Esfandyarpour et al. 2010/0255555 A1 2/2010 Rothberg et al. 2014/0335457 A1 8/2014 Esfandyarpour et al. 2010/0255555 A1 2/2010 Rothberg et al. 2014/03304557 A1 8/2014 Esfandyarpour et al. 2010/0300859 A1 2/2010 Rothberg et al. 2014/03304567 A1 4/2014 Esfandyarpour et al. 2010/03008559 A1 2/2010 Rothberg et al. 2014/0335457 A1 8/2014 Esfandyarpour et al. 2010/03008559							
2009/0026082 A1							
2009/002385 Al 1/2009 Christians et al. 2012/0258499 Al 10/2012 Piepenburg et al. 2009/0032401 Al * 2/2009 Chromathies at al. 2012/0295819 Al 11/2012 Leamon et al. 2012/0302454 Al 11/2012 Esfandyarpour et al. 2012/0302454 Al 11/2012 Esfandyarpour et al. 2012/0302454 Al 11/2012 Esfandyarpour et al. 2009/0166221 Al 7/2009 Salasubramanian et al. 2013/0005613 Al 1/2013 Erlander et al. 2009/0170724 Al 7/2009 Balasubramanian et al. 2013/0033011 Al 1/2013 Leamon et al. 2009/0191594 Al 7/2009 Ohashi 2013/0034880 Al 2/2013 Clohberg et al. 2013/0035252 Al 2/2010 Carbierg et al. 2013/0059762 Al 3/2013 Armes et al. 2010/007208 Al 3/2010 Carbierg et al. 2013/0096013 Al 4/2013 Sikora et al. 2010/017288 Al 5/2010 Farinas et al. 2013/0096013 Al 4/2013 Sikora et al. 2010/0173743 Al 6/2010 Farinas et al. 2013/025421 Al 8/2013 Esfandyarpour et al. 2010/0151479 Al 6/2010 Rothberg et al. 2013/025312 Al 2/2013 Esfandyarpour et al. 2010/0153441 Al 6/2010 Toumazou et al. 2013/025313 Al 2/2014 Esfandyarpour et al. 2010/0163414 Al 7/2010 Gillies et al. 2014/0073531 Al 3/2014 Esfandyarpour et al. 2010/0167938 Al 7/2010 Gillies et al. 2014/0073531 Al 3/2014 Esfandyarpour et al. 2010/0167938 Al 7/2010 Rothberg et al. 2014/0035457 Al 8/2014 Esfandyarpour et al. 2010/0255595 Al 2010 Rothberg et al. 2014/0235457 Al 8/2014 Esfandyarpour et al. 2010/0255595 Al 20210 Rothberg et al. 2014/033699 Al 1/2014 Esfandyarpour et al. 2010/0300895 Al 2/2010 Rothberg et al. 2010/0300895 Al							
2009/0048124 A1 2/2009 Leamon et al. 2012/0302454 A1 11/2012 Leamon et al. 2009/0167389 A1 5/2009 Schiberg et al. 2012/0302454 A1 11/2012 Esfandyarpour et al. 2009/01670724 A1 7/2009 Balasubramanian et al. 2013/0025613 A1 1/2013 Leamon et al. 2009/0181385 A1 7/2009 McKernan et al. 2013/0023011 A1 1/2013 Leamon et al. 2009/0191594 A1 7/2009 McKernan et al. 2013/0034880 A1 2/2013 Oldham 2010/0035252 A1 2/2010 Rothberg et al. 2013/0059290 A1 3/2013 Armes et al. 2010/0078080 A1 3/2010 Karhanek et al. 2013/0090860 A1 4/2013 Sikora et al. 2010/013743 A1 6/2010 Rothberg et al. 2013/0090860 A1 4/2013 Esfandyarpour et al. 2010/0137413 A1 6/2010 Rothberg et al. 2013/0231254 A1 9/2013 Lie tal. 2010/0151479 A1 6/2010 Rothberg et al. 2013/0231254 A1 9/2013 Kawashima et al. 2010/015341 A1 6/2010 Rothberg et al. 2013/0231254 A1 9/2013 Kawashima et al. 2010/015344 A1 7/2010 Gillies et al. 2013/023135 A1 3/2014 Esfandyarpour et al. 2010/0157339 A1 2/2014 Esfandyarpour et al. 2010/0163414 A1 7/2010 Gillies et al. 2014/0073531 A1 3/2014 Esfandyarpour et al. 2010/0167938 A1 7/2010 Rothberg et al. 2014/00336487 A1 4/2014 Esfandyarpour 2010/0167938 A1 7/2010 Rothberg et al. 2014/0235457 A1 8/2014 Esfandyarpour 2010/0209922 A1 8/2010 Rothberg et al. 2014/0329699 A1 1/2014 Esfandyarpour 2010/02055595 A1 10/2010 Rothberg et al. 2014/0329699 A1 1/2014 Esfandyarpour 2010/02055595 A1 10/2010 Rothberg et al. 2014/0329699 A1 1/2014 Esfandyarpour 2010/0300559 A1 1/2010 Rothberg et al. 2014/0329699 A1 1/2014 Esfandyarpour 2010/0300559 A1 1/2010 Rothberg et al. 2014/0329699 A1 1/2014 Esfandyarpour 2010/0300559 A1 1/2010 Rothberg et al. 2010/0300559 A1 1/2010 Rothberg et al. 2010/0301398 A1 1/2010 Rothberg et al. 2010/0301398							
2009/0127589 A1 5/2009 Rothberg et al. 2012/0302454 A1 11/2012 Esfandyarpour et al.							
2009/0166221 A1 7/2009 Ishige et al. 2012/0322113 A1 1/2/012 Erlander et al. 2009/0170724 A1 7/2009 Balasubramanian et al. 2013/0005613 A1 1/2013 Leamon et al. 2009/0191594 A1 7/2009 McKernan et al. 2013/0034880 A1 2/2013 Oldham 2010/0035252 A1 2/2010 Rothberg et al. 2013/0034880 A1 2/2013 Oldham 2010/0072080 A1 3/2010 Karhanek et al. 2013/0059762 A1 3/2013 Leamon et al. 2010/0078325 A1 4/2010 Oliver 2013/0090860 A1 4/2013 Sikora et al. 2010/0112588 A1 5/2010 Farinas et al. 2013/0090860 A1 4/2013 Esfandyarpour et al. 2010/0137143 A1 6/2010 Rothberg et al. 2013/0225421 A1 8/2013 Li et al. 2010/0151479 A1 6/2010 Toumazou et al. 2013/0231254 A1 9/2013 Kawashima et al. 2010/0159461 A1 6/2010 Toumazou et al. 2013/0231254 A1 9/2013 Li et al. 2010/0163414 A1 7/2010 Gillies et al. 2014/0073531 A1 3/2014 Esfandyarpour et al. 2010/016398 A1 7/2010 Rothberg et al. 2014/0099674 A1 4/2014 Esfandyarpour et al. 2010/0197507 A1 8/2010 Rothberg et al. 2014/0235457 A1 8/2014 Esfandyarpour et al. 2010/0255595 A1 10/2010 Rothberg et al. 2014/0329699 A1 11/2014 Esfandyarpour et al. 2010/0255595 A1 10/2010 Toumazou et al. 2014/0329699 A1 11/2014 Esfandyarpour et al. 2010/0255595 A1 10/2010 Toumazou et al. 2014/0300559 A1 12/2010 Schultz et al. 2010/0300559 A1 12/2010 Schultz et al. 2010/0300559 A1 12/2010 Schultz et al. 2010/0300559 A1 12/2010 Schultz et al. 2010/0300398 A1 12/2010 Rothberg et al. 2010/0300398 A1 12/2010 Rothberg et al. 2010/0300398 A1 12/2010 Rothberg et al. EP 1499738 B1 7/2008							
2009/0170724				2012/0322113	A1		
2009/0191593							
2010/0035252	2009/0181385 A1						
2010/0072080 A1 3/2010 Karhanek et al. 2013/0059762 A1 3/2013 Leamon et al. 2010/0078325 A1 4/2010 Oliver 2013/0090860 A1 4/2013 Sikora et al. 2010/0112588 A1 5/2010 Farinas et al. 2013/00908013 A1 4/2013 Esfandyarpour et al. 2010/0137143 A1 6/2010 Rothberg et al. 2013/0225421 A1 8/2013 Li et al. 2010/0137413 A1 6/2010 Rothberg et al. 2013/0231254 A1 9/2013 Kawashima et al. 2010/0151479 A1 6/2010 Toumazou et al. 2013/0281307 A1 10/2013 Li et al. 2010/0159461 A1 6/2010 Toumazou et al. 2014/0057339 A1 2/2014 Esfandyarpour et al. 2010/0163414 A1 7/2010 Gillies et al. 2014/0073531 A1 3/2014 Esfandyarpour 2010/0167938 A1 7/2010 Su et al. 2014/0099674 A1 4/2014 Piepenburg et al. 2010/0197507 A1 8/2010 Rothberg et al. 2014/0235457 A1 8/2014 Esfandyarpour 2010/0209922 A1 8/2010 Rothberg et al. 2014/0329699 A1 11/2014 Esfandyarpour 2010/0255595 A1 10/2010 Toumazou et al. 2015/0148264 A1 5/2015 Esfandyarpour et al. 2010/0282617 A1 11/2010 Rothberg et al. 2010/0300895 A1 12/2010 Schultz et al. FOREIGN PATENT DOCUMENTS 2010/0300895 A1 12/2010 Rothberg et al. CN 101848757 A 9/2010 2010/0301398 A1 12/2010 Rothberg et al. EP 1499738 B1 7/2008 P. 2010/0300895 P.							
2010/0078325 A1							
2010/0112588 A1 5/2010 Farinas et al. 2013/0096013 A1 4/2013 Esfandyarpour et al. 2010/0137143 A1 6/2010 Rothberg et al. 2013/0225421 A1 8/2013 Li et al. 2013/021544 A1 9/2013 Li et al. 2013/021544 A1 9/2013 Li et al. 2013/021544 A1 10/2013 Li et al. 2013/021547 A1 10/2013 Li et al. 2013/02154 A1 10/2013 Li et al. 2013/02154 A1 2013/02154 A1 2013/02154 A1 2014/057339 A1 2/2014 Esfandyarpour et al. 2014/0073531 A1 3/2014 Esfandyarpour et al. 2010/0163414 A1 7/2010 Gillies et al. 2014/0073531 A1 3/2014 Esfandyarpour 2010/0188073 A1 7/2010 Rothberg et al. 2014/0235457 A1 8/2014 Esfandyarpour 2010/0197507 A1 8/2010 Rothberg et al. 2014/0329699 A1 11/2014 Esfandyarpour 2010/0209922 A1 8/2010 Williams et al. 2015/0148264 A1 5/2015 Esfandyarpour et al. 2010/0285595 A1 10/2010 Toumazou et al. 2010/0282617 A1 11/2010 Rothberg et al. FOREIGN PATENT DOCUMENTS 2010/0300895 A1 12/2010 Rothberg et al. CN 101848757 A 9/2010 2010/0301398 A1 12/2010 Rothberg et al. EP 1499738 B1 7/2008 A1 A1/2008 A							
2010/0301398 A1 10/2010 Rothberg et al. 2013/0231254 A1 9/2013 Kawashima et al. 2010/0301398 A1 10/2014 E1 2010/0300895 A1 10/2016 Rothberg et al. 2013/0281307 A1 10/2013 Li et al. 2010/0301398 A1 10/2014 Esfandyarpour et al. 2014/0057339 A1 2/2016 E2 2014/0073531 A1 3/2014 Esfandyarpour et al. 2010/0167938 A1 7/2010 Rothberg et al. 2014/0099674 A1 4/2014 Esfandyarpour A1 2010/0188073 A1 7/2010 Rothberg et al. 2014/0325457 A1 8/2014 Esfandyarpour 8/2010 Rothberg et al. 2014/0329699 A1 11/2014 Esfandyarpour 2010/0209922 A1 8/2010 Williams et al. 2015/0148264 A1 5/2015 Esfandyarpour et al. 2010/0282617 A1 11/2010 Rothberg et al. FOREIGN PATENT DOCUMENTS 2010/0300855 A1 12/2010 Rothberg et al. CN 101848757 A 9/2010 2010/0301398 A1 12/2010 Rothberg et al. EP 1499738 B1 7/2008 P. 101848757 A 9/2010 P							
2010/03018965 A1 12/2010 Rothberg et al. 2013/0281307 A1 10/2013 Li et al.							
2010/0300895 A1 12/2010 Rothberg et al. 2014/035739 A1 2/2014 Esfandyarpour et al. 2010/0300895 A1 12/2010 Rothberg et al. 2014/03531 A1 3/2014 Esfandyarpour et al. 2010/0300895 A1 12/2010 Rothberg et al. 2014/035739 A1 2/2014 Esfandyarpour et al. 2010/0300895 A1 12/2010 Rothberg et al. 2014/035351 A1 3/2014 Esfandyarpour et al. 2010/0300895 A1 12/2010 Rothberg et al. 2014/0329699 A1 11/2014 Esfandyarpour et al. 2010/0300895 A1 12/2010 Rothberg et al. 2015/0148264 A1 5/2015 Esfandyarpour et al. 2010/0300895 A1 12/2010 Rothberg et al. FOREIGN PATENT DOCUMENTS 2010/0301398 A1 12/2010 Rothberg et al. EP 1499738 B1 7/2008 7/2008 A1 12/2010 Rothberg et al. EP 1499738 B1 7/2008 A1 12/2010 A1 A1 A1 A1 A1 A1 A1							
2010/0163414 A1 7/2010 Gillies et al. 2014/0073531 A1 3/2014 Esfandyarpour							
2010/0188073 A1 7/2010 Rothberg et al. 2014/0235457 A1 8/2014 Esfandyarpour 2010/0197507 A1 8/2010 Rothberg et al. 2014/0329699 A1 11/2014 Esfandyarpour 2010/0209922 A1 8/2010 Williams et al. 2015/0148264 A1 5/2015 Esfandyarpour et al. 2010/0255595 A1 10/2010 Tournazou et al. 2010/0282617 A1 11/2010 Rothberg et al. FOREIGN PATENT DOCUMENTS 2010/0300559 A1 12/2010 Schultz et al. 2010/0300895 A1 12/2010 Rothberg et al. 2010/				2014/0073531	A1		, <u>,</u>
2010/0197507 A1 8/2010 Rothberg et al. 2014/0329699 A1 11/2014 Esfandyarpour 2010/0209922 A1 8/2010 Williams et al. 2015/0148264 A1 5/2015 Esfandyarpour et al. 2010/0255595 A1 10/2010 Toumazou et al. FOREIGN PATENT DOCUMENTS 2010/0300559 A1 12/2010 Schultz et al. 2010/0300895 A1 12/2010 Nobile et al. CN 101848757 A 9/2010 2010/0301398 A1 12/2010 Rothberg et al. EP 1499738 B1 7/2008	2010/0167938 A1	7/2010	Su et al.				
2010/0209922 A1 8/2010 Williams et al. 2015/0148264 A1 5/2015 Esfandyarpour et al. 2010/0255595 A1 10/2010 Toumazou et al. FOREIGN PATENT DOCUMENTS 2010/0300559 A1 12/2010 Schultz et al. 2010/0300895 A1 12/2010 Nobile et al. CN 101848757 A 9/2010 2010/0301398 A1 12/2010 Rothberg et al. EP 1499738 B1 7/2008							
2010/0255595 A1 10/2010 Toumazou et al. 2010/0282617 A1 11/2010 Rothberg et al. FOREIGN PATENT DOCUMENTS 2010/0300559 A1 12/2010 Schultz et al. 2010/0300895 A1 12/2010 Nobile et al. CN 101848757 A 9/2010 2010/0301398 A1 12/2010 Rothberg et al. EP 1499738 B1 7/2008							
2010/0282617 A1 11/2010 Rothberg et al. FOREIGN PATENT DOCUMENTS 2010/0300559 A1 12/2010 Schultz et al. 2010/0300895 A1 12/2010 Nobile et al. CN 101848757 A 9/2010 2010/0301398 A1 12/2010 Rothberg et al. EP 1499738 B1 7/2008				2013/0170204	2 3 1	5/2013	Lorandyaipour et ai.
2010/0300559 A1 12/2010 Schultz et al. 2010/0300895 A1 12/2010 Nobile et al. CN 101848757 A 9/2010 2010/0301398 A1 12/2010 Rothberg et al. EP 1499738 B1 7/2008				FO	REIG	N PATE	NT DOCUMENTS
2010/0301398 A1 12/2010 Rothberg et al. EP 1499738 B1 7/2008		12/2010	Schultz et al.				
· ·							
2010/0504702 A1 12/2010 Hillz et al. EF 1992/00 A2 11/2008							
	2010/030 4 982 Al	12/2010	TIMZ St dl.	151	1392	.100 AZ	11/2000

(56)	Reference	es Cited
	FOREIGN PATEN	T DOCUMENTS
EP	2290096 A2	3/2011
EP	2336361 A2	6/2011
EP	2428588 A2	3/2012
EP	2287341 B1	2/2013
EP	1759012 B1	5/2013
EP	2660336 A1	11/2013
WO	WO 01/18246 A1	3/2001
WO	WO-0137958 A2	5/2001
WO	WO 01/42508 A2	6/2001
WO	WO-0227909 A2	4/2002
WO	WO 02/061146 A1	8/2002
WO	WO 2005/008450 A2	1/2005
WO	WO 2005/108612 A2	11/2005
WO	WO 2005/121363 A2	12/2005
WO	WO-2007041619 A2	4/2007
WO	WO 2007/098049 A2	8/2007
WO	WO 2008/076406 A2	6/2008
WO	WO 2009/012112 A2	1/2009
WO	WO 2009/052348 A2	4/2009
WO	WO-2009074926 A1	6/2009
WO	WO 2009/122159 A2	10/2009
WO	WO 2009/150467 A1	12/2009
WO	WO 2010/008480 A2	1/2010
WO	WO 2010/075188 A2	1/2010
WO	WO 2010/037085 A1	4/2010
WO	WO 2010/047804 A2	4/2010
WO	WO 2010/138187 A1	12/2010
WO	WO 2010/141940 A1	12/2010
WO	WO 2011/106556 A2	9/2011
WO	WO 2012/047889 A2	4/2012
WO	WO 2014/012107 A2	1/2014
WO	WO 2014/043143 A1	3/2014

OTHER PUBLICATIONS

U.S. Appl. No. 13/838,816, filed Mar. 15, 2013, Esfandyarpour et al. Esfandyarpour, et al. 3D modeling of impedance spectroscopy for protein detection in nanoneedle biosensors. Proceedings of the COMSOL Conference 2007, Boston.

Finn, et al. Efficient incorporation of positively charged 2', 3'-dideoxynucleoside-5'-triphosphates by DNA polymerases and their application in 'direct-load' DNA sequencing. Nucleic Acids Res. Aug. 15, 2003;31(16):4769-78.

Hollis, et al. Structure of the gene 2.5 protein, a single-stranded DNA binding protein encoded by bacteriophage T7. Proc Natl Acad Sci U S A. Aug. 14, 2001;98(17):9557-62. Epub Jul. 31, 2001.

International search report and written opinion dated Feb. 26, 2013 for PCT/US2012/039880.

International search report and written opinion dated Mar. 19, 2013 for PCT/US2012/067645.

International search report and written opinion dated Apr. 13, 2012 for PCT/US2011/054769.

Kitano, et al. Molecular structure of RNA polymerase and its com-

plex with DNA. J Biochem. Jan. 1969;65(1):1-16. Office action dated Jul. 18, 2013 for U.S. Appl. No. 13/481,858.

Office action dated Nov. 5, 2013 for U.S. Appl. No. 13/632,5138. Ren, et al. Rapid and sensitive detection of hepatitis B virus 1762T/

Ren, et al. Rapid and sensitive detection of hepatitis B virus 1762T/1764A double mutation from hepatocellular carcinomas using LNA-mediated PCR clamping and hybridization probes. Journal of Virological Methods. 2009; 158:24-29.

Senapati, et al. A nonamembrane-based nucleic acid sensing platform for portable diagnostics. Topics in Current Chemistry. 2011; 304:153-169.

Voelkerding, et al. Next generation sequencing: from basic research to diagnostics. Clin. Chem. 2009; 55(4):641-658.

U.S. Appl. No. 14/119,859, filed Nov. 22, 2013, Esfandyarpour et al. Office action dated Jan. 28, 2014 for U.S. Appl. No. 13/838,816. Office action dated Jan. 29, 2014 for U.S. Appl. No. 13/481,858.

Daniels, et al. Label-Free Impedance Biosensors: Opportunities and Challenges. Electroanalysis. May 16, 2007;19(12):1239-1257.

Daniels, et al. Simultaneous Measurement of Nonlinearity and Electrochemical Impedance for Protein Sensing Using Two-Tone Excitation. 30th Annual International IEEE EMBS Conference. Vancouver, British Columbia, Canada, Aug. 20-24, 2008. 5753-5756.

European search report and search opinion dated Mar. 12, 2014 for EP Application No. 11831452.5.

Piepenburg, et al. DNA detection using recombination proteins. PLoS Biol. Jul. 2006;4(7):e204.

U.S. Appl. No. 14/596,111, filed Jan. 13, 2015, Esfandyarpour et al. Esfandyarpour, et al. A Novel Nanoneedle Biosensor for DNA Sequencing (abstract). Dec. 31, 2008. Available at http://www.nsti.org/Nanotech2008/showabstract.html?absno=1522.

European search report and search opinion dated Jan. 5, 2015 for EP Application No. 12792216.9.

Margulies, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature. Sep. 15, 2005;437(7057):376-80. Epub Jul. 31, 2005.

Office action dated Dec. 19, 2014 for U.S. Appl. No. 13/838,816. U.S. Appl. No. 14/361,902, filed May 30, 2014, Esfandyarpour.

International search report and written opinion dated Aug. 21, 2014 for PCT Application No. PCT/US2014/027544.

Javanmard, et al. A microfluidic platform for electrical detection of DNA hybridization. Sens Actuators B Chem. May 20, 2011;154(1):22-27. Epub Mar. 30, 2010.

Office action dated Sep. 2, 2014 for U.S. Appl. No. 13/632,513.

Cagnin, et al. Overview of electrochemical DNA biosensors: new approaches to detect the expression of life. Sensors (Basel). 2009;9(4):3122-48. doi: 10.3390/s90403122. Epub Apr. 24, 2009.

Manickam, et al. A CMOS Electrochemical Impedance Spectroscopy (EIS) Biosensor Array. IEEE Trans Biomed Circuits Syst. Dec. 2010;4(6):379-90. doi: 10.1109/TBCAS.2010.2081669.

Office action dated Jul. 25, 2014 for U.S Appl. No. 13/481,858.

Sabounchi, et al. Sample concentration and impedance detection on a microfluidic polymer chip. Biomed Microdevices. Oct. 2008;10(5):661-70. doi: 10.1007/s10544-008-9177-4.

Notice of allowance dated Nov. 21, 2014 for U.S. Appl. No. 13/632 513

Co-pending U.S. Appl. No. 14/688,764, filed Apr. 16, 2015.

Notice of allowance dated Jun. 3, 2015 for U.S. Appl. No. 14/596,111.

Lee, et al. Ion-sensitive field-effect transistor for biological sensing. Sensors (Basel). 2009;9(9):7111-31. doi: 10.3390/s90907111. Epub Sep. 7, 2009.

Office action dated Jan. 30, 2015 for U.S. Appl. No. 13/481,858.

Office action dated Apr. 9, 2015 for U.S. Appl. No. 14/596,111.

Co-pending U.S. Appl. No. 14/653,230, filed Jun. 17, 2015. European search report and search opinion dated Jul. 13, 2015 for EP

Application No. 12852490.7.

Notice of allowance dated Jul. 13, 2015 for U.S. Appl. No. 14/596,111.


Edman; et al., "Electric field directed nucleic acid hybridization on microchips.", Dec. 15, 1997, 25(24), 4907-14.

Sosnowski; et al., "Rapid determination of single base mismatch mutations in DNA hybrids by direct electric field control.", Feb. 18, 1997, 94(4), 1119-23.


Zhang; et al., "Dielectrophoresis for manipulation of micro/nano particles in microfluidic systems.", Jan. 2010, 396(1), 401-20. Co-pending U.S. Appl. No. 14/835,070, filed Aug. 25, 2015.


Notice of allowance dated Aug. 25, 2015 for U.S. Appl. No. 14/596,111.


^{*} cited by examiner




~ O L













<</p>





ぬ じ エ
























FIG. 84










<u>С</u>










© © €










S C U














© ©























SYSTEMS AND METHODS FOR AUTOMATED REUSABLE PARALLEL BIOLOGICAL REACTIONS

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to and benefit of U.S. Provisional Application Ser. No. 61/389,490, entitled "Integrated System and Methods for Polynucleotide Extraction, Amplification and Sequencing," filed Oct. 4, 2010; 61/389,484, entitled "Magnetic Arrays for Emulsion-Free Polynucleotide Amplification and Sequencing," filed Oct. 4, 2010; 61/443, 167, entitled "Chamber-Free Gene Electronic Sequencing Technologies," filed Feb. 15, 2011; and 61/491,081, entitled "Methods and Systems for Nucleic Acid Sequencing," filed May 27, 2011, each of which is incorporated herein by reference in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

This invention was made with government support under a Qualifying Therapeutic Discovery Grant awarded by the IRS, in conjunction with the Department of Health and Human ²⁵ Services. The U.S. government has certain rights in the invention

BACKGROUND

Methods for quick and cost effective DNA sequencing (e.g., at high-throughput) remain an important aspect of advancing personalized medicine and diagnostic testing. Some known systems for DNA sequencing require that DNA samples be transferred between various subsystems (e.g., 35 between the nucleic acid isolation subsystem and the amplification subsystem), thus resulting in inefficiencies and potential contamination. Some known methods for DNA sequencing employ optical detection, which can be cumbersome, expensive, and can limit throughput. Other systems 40 utilize some forms of electronic sensing, but the sensor and sequencing flow cell are one-time use disposables, which substantially increase the cost to the user, and limits the complexity of the sensor which may be cost effectively manufactured, as it will be thrown out after a single use. Some 45 systems utilize amplification methods within the same flow cell, in which the sequencing is performed, binding the amplified directly to the flow cell, preventing reuse. Other systems utilize emulsion PCR, wherein beads and samples are mixed into small emulsions utilizing low concentrations. Due to 50 Poisson distribution, most of the beads and sample do not come together in an emulsion with a single bead and a single sample, and are thus lost. The cost of the beads is a substantial portion of the cost of the sequencing, and most of that cost is thrown away without ever generating any useful data. The 55 current system enables utilization of virtually all of the sample, and the reuse of the beads, thus reducing the cost to the user.

Current DNA sequencing systems typically need whole genome amplification in order to have sufficient sample, as 60 the sample is very inefficiently utilized. Such whole genome amplification methods typically introduce significant amounts of bias in amplification in different portions of the genome, and require higher levels of coverage to overcome said bias. Methods for localizing samples, and reagents into a 65 volume wherein a desired reaction or binding may occur is another aspect which is envisioned for the system, which may

2

eliminate or reduce the need for whole genome amplification, and thus reduce the coverage needed.

Thus, a need exists for improved systems and methods for extracting, amplifying and sequencing polynucleotides

SUMMARY

The embodiments described herein relate to systems and methods for extracting, amplifying and sequencing polynucleotides. In some embodiments, the systems and methods can include a fully-automated, integrated platform, thereby reducing the cost, improving throughput and/or simplifying the methods of use.

In one aspect, the invention provides a method for isolating biological material, reactants, and/or reaction byproducts for a reaction, such as a nucleic acid amplification or sequencing reaction. The method comprises magnetically holding a bead carrying biological material (e.g., nucleic acid, which may be in the form of DNA fragments or amplified DNA) in a specific 20 location of a substrate, and applying an electric field local to the bead to isolate the biological material or products or byproducts of reactions of the biological material. For example, the bead is isolated from other beads having associated biological material. The electric field in various embodiments concentrates reagents for an amplification or sequencing reaction, and/or concentrates and isolates detectable reaction by-products. For example, by isolating nucleic acids around individual beads, the electric field can allow for clonal amplification, as an alternative to emulsion PCR. In other embodiments, the electric field isolates a nanosensor proximate to the bead, to facilitate detection of at least one of local pH change, local conductivity change, local charge concentration change and local heat. The beads may be trapped in the form of an array of localized magnetic field regions.

In another aspect, the invention provides a method for conducting nucleic acid amplification and/or sequencing. The method comprises applying an electric field for confinement of a biological material to an environment, and conducting nucleic acid amplification and/or nucleic acid sequencing on the biological material. The confinement of the environment from an external environment via the electric field has the effect of isolating the biological material into a plurality of regions. The confinement creates a virtual well facilitating amplification and/or detection, and preventing contamination between virtual wells. In various embodiments, the biological material is associated with a plurality of beads, and the beads are held in place by a localized magnetic field in each of the plurality of regions. In certain embodiments, amplification within the virtual wells generates a clonal population of DNA associated with each of the beads, or on the surface of a sensor.

In another aspect, the invention provides an automated method for separating a population of beads carrying amplified nucleic acids, from a population of beads not carrying amplified nucleic acids. The method comprises separating the populations of beads based on a charge associated with the beads. The separation may be implemented with electrophoresis. The bead separation may be based on a flow-through mechanism, and the beads may be reused in a subsequent amplification reaction, for example, by treating the beads so as to remove any amplified product and/or primer.

In still other aspects, the invention provides a method for purifying DNA fragments from a biological material. The method comprises applying an electric field in a fluidic environment, said fluidic environment at least partially containing a filter medium. In this aspect, the electric field is adapted to separate a DNA fragment from a biological material as the

biological material is conveyed through the filter medium. In various embodiments, the filter medium is a porous membrane or a medium providing a different mobility of the DNA fragments compared to a remainder of the biological material. Once purified, the DNA fragments can be used for DNA 5 library construction, DNA amplification, DNA enrichment, and/or DNA sequencing, for example, using the methods and systems described herein.

In yet another aspect, the invention provides a method for shearing DNA isolated from a biological material. The 10 method comprises disposing a plurality of particles in a fluidic environment containing a population of DNA molecules, and causing flow of the particles in the fluidic environment to produce a shearing force on the DNA molecules in order to produce DNA fragments. In such embodiments, the shearing 15 force produces blunt ends to aid in subsequent library construction.

In another aspect, the invention provides a system for nucleic acid amplification and/or sequencing. The system comprises a substantially planar substrate coupled to a moiety 20 for binding a nucleic acid to the substrate, and a means for separating the nucleic acid from the substrate such that the system is reusable for at least one of nucleic acid amplification and nucleic acid sequencing. During amplification, the system generates nucleic acid clones on the surface of the 25 substrate. Amplification may involve either heating cycles or by isothermal amplification. In various embodiments, the system further comprises an instrument for detecting incorporation of a nucleotide in a sequencing reaction. The detection may be based on at least one of local pH change, local 30 heat detection, local capacitance change and a local charge concentration and local conductivity change.

In some aspects, the invention provides a system for detecting biological material or a biological reaction product or byproduct. The system comprises a substantially planar sensor array, the sensor array comprising a means for capturing a bead adjacent to each nanosensor in the array. The nanosensor is capable of detecting biological material or a biological reaction product or byproduct. The system further comprises a means for releasing a bead to facilitate reuse of the array, 40 such as by magnetic, chemical, enzymatic means.

In some embodiments of the methods and systems described herein, an apparatus includes a substrate, a porous member and an electrode. The substrate defines a microfluidic channel configured to receive a sample. The porous member is disposed at least partially within the microfluidic channel. The electrode is configured to produce an electric field, and is coupled to the microfluidic channel such that at least a portion of the porous member may be disposed within the electric field. The porous member and the electric field may be separated from the sample when the sample is conveyed the field by a mat through the porous member.

In an apparatus includes a substrate, a porous amplification. FIG. 10 de chip.

FIG. 11 shands a concern field, and a concern field may be a simulation. FIG. 13 shands a simulation. FIG. 14 shands a simulation.

In some embodiments, an apparatus includes a substrate, a plurality of particles and a flow mechanism. The substrate 55 may define a microfluidic channel configured to receive a sample containing a plurality of DNA molecules. In other embodiments, the apparatus may be used as a probe and inserted into a well or other fluidic environment. The plurality of particles may be configured to be disposed within the 60 microfluidic channel. The mechanism for producing the flow may be configured to produce a flow of the sample and the plurality of particles within the microfluidic channel such that the plurality of particles produces a shear force on the plurality of DNA molecules to produce a plurality of DNA fragments. In some embodiments, an on-chip peristaltic pump, made of multiple fluidic gates with orthogonal control and

4

flow channels (Valve Technology), or an external pressure may generate the required flow in the channel.

The present invention provides magnetic arrays and methods of using the magnetic arrays for polynucleotide amplification and sequence analysis, thereby providing fast, convenient, and/or low-cost DNA sequencing.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A shows beads and a magnetic array with sensors which may be used to capture the beads.

FIG. 1B shows the beads captured on the magnetic array in a one to one correspondence with the sensors.

FIG. 1C shows the sensor array after the beads have been washed off ready for use for the next sample.

FIG. 1D shows a schematic of a sensor array used with a set of nonspherical magnetic particles.

FIGS. 2A-2B Show a photomicrographs of a magnetic arrays according to an embodiment loaded with beads

FIGS. **3** and **4** are schematic illustrations of the reaction involved in incorporating nucleotides into a growing DNA strand, showing the release of pyrophosphate and concomitant increase in pH and heat release.

FIG. **5**A shows a schematic illustration of a series of nanosensors in electrical communication with the microfluidic channels of the sequencing system.

FIG. 5B depicts a graph showing output of a sequencing operation performed via a sequencing apparatus.

FIG. 6 shows an array of electronic sensors with a set of electrodes used for concentration or confinement of multiple charged moieties above the sensors.

FIG. 7 shows magnetic or electric or electromagnetic retention of a clonal bead held in place for sequencing over a sensor.

FIG. 8A depicts an image of a portion of the sequencing system that includes the nanosensors.

FIG. **8**B shows a schematic illustration of a nanosensor, and a series of nanosensors in electrical communication with the microfluidic channels of the sequencing system.

FIG. 9 shows a schematic illustration of an array of nanosensors within the sequencing system. The on-chip amplification is optional.

FIG. 10 depicts components of an exemplary sequencing chip.

FIG. 11 shows the electric forces, a schematic embodiment and a concentration diagram from a simulation.

FIG. 12 shows the stream line electric field and the electric potential at a horizontal cross line above the electrodes from a simulation.

FIG. 13 shows a fluorescent micrograph of DNA on beads held by a magnetic array.

FIG. 14 shows a sensor with electrodes for creating electrophoretic concentration/confinement fields for attracting a sample molecule and confining the amplification reaction, and its use in an amplification reaction.

FIG. 15 shows an array of electrical confinement electrodes and sensors in a one to one correspondence.

FIG. **16**A shows a set of beads with clonal DNA attached thereto and a sensor and magnetic array.

FIG. **16**B shows the set of beads captured wherein each captured DNA covered bead is held in place over a sensor.

FIG. 16C shows a second set of beads and a sensor and magnetic confinement array which are partially populated with beads.

FIG. 16D shows two sets of beads captured by a sensor and the magnetic confinement array of FIG. 16C.

FIG. 17 shows a sensor with electrodes for creating electrophoretic concentration/confinement fields used for amplification and sequencing reactions

FIGS. 18A-B illustrate different views of one embodiment of a bead separation system

FIG. 19 is a schematic illustration of an integrated platform for extracting, amplifying and sequencing polynucleotides according to an embodiment.

FIGS. **20-24** show embodiments of the microfluidic portions of the integrated platform for extracting, amplifying and sequencing polynucleotides.

DETAILED DESCRIPTION

As used herein, "bead capture features" may mean features that can temporarily hold a single bead in a fixed position relative to the sensor and can include local magnetic structures on the substrate, depressions which may utilize an external magnet, local magnetic structures, Van der Waals forces, or gravity as forces that fix the position of a bead. Optionally, the bead may be bound in place using covalent or non-covalent binding.

As used herein, "clonal" may mean that substantially all of the populations of a bead or particle are of the same nucleic 25 acid sequence. In some embodiments there may be two populations associated with a single sample DNA fragment, as would be desired for "mate pairs," "paired ends", or other similar methodologies; the populations may be present in roughly similar numbers on the bead or particle, and may be 30 randomly distributed over the bead or particle.

As used herein, "confinement" may mean when a molecule generated (such as DNA) at one bead or particle stays associated with the same bead or particle so as to substantially maintain the clonal nature of the beads or particles.

As used herein "isolate" may mean the prevention of migration, diffusion, flow, or other movement, from one virtual well to another virtual well as necessary to maintain the clonal nature of the beads or particles.

As used herein, "localized magnetic feature" may mean a magnetic feature created on a substantially planar substrate to hold individual beads on said substantially planar substrate.

As used herein, "localized magnetic field" may mean a magnetic field that substantially exists in the volume between 45 the north pole of a first magnetic region and the south pole of a second magnetic region or substantially exists in the volume between the north and south poles of a single magnetic region.

As used herein, "localized electric field" may mean an 50 electric field that substantially exists in the volume between at least two electrodes.

As used herein, "nanosensor" may mean a sensor designed to detect beads or particles less than one of 0.1, 1, 5, 10 or 20 micrometers as measured on the diameter or the long axis for non spherical beads or particles. Alternatively, the sensor may be sensitive to moieties associated with said beads or particles, or with reaction products or byproducts wherein the reaction includes a moiety associated with said bead or particle. Said moieties may include DNA fragments, hydrogen ions, or other ions which are counter ions and thus associated with said beads or particles or moieties bound or associated with said beads or particles.

Nanosensors can include "NanoBridge, "NanoNeedle, 65 ISFET, ChemFET, nano-calorimeter or cantilever based pH sensors or combinations thereof.

6

As used herein, "particle" can mean a non spherical moiety such as a molecule, an aggregation of molecules, molecules bound to a solid particle, or particles, and other forms known in the art.

As used herein, "single phase liquid" is a liquid with relatively uniform physical properties throughout, including such properties as density, index of refraction, specific gravity, and can include aqueous, miscible aqueous and organic mixtures but does not include non miscible liquids such as oil and water. Among the physical properties not considered to potentially cause a liquid to not be considered a single phase liquid include local variations in pH, charge density, and ionic concentration or temperature.

As used herein, "Substantially planar" shall allow small pedestals, raised sections, holes, depressions, or asperity which does not exceed 50 µm relative to the local plane of the device. Variations due to warpage, twist, cupping or other planar distortions are not considered to constitute a portion of the permitted offset. Protrusions or depressions which are not essential for the uses as described herein but which exceed 50 µm do not preclude a device from being considered substantially planar. Fluidic channels and or structures to generate said fluidic channels which have dimensions of greater than 50 µm also do not preclude a device from being considered substantially planar.

As used herein, "virtual wells" refers to local electric field or local magnetic field confinement zones where the species or set of species of interest, typically DNA or beads, substantially does not migrate into neighboring "virtual wells" during a period of time necessary for a desired reaction or interaction.

In some embodiments of the current invention, the invention provides an automated reusable system for performing a sequencing chemistry. In some embodiments a chemistry method performed by the system may include sequencing by synthesis, which is schematically shown in FIG. 3, wherein dNTPs bind to a complex which may include a colony of DNA, complementary primers, and polymerase. The polymerase incorporates the dNTP to the growing extended primer, and creates as byproducts of said incorporation hydrogen ions, pyrophosphate and heat which can be detected by electronic sensors. By determining whether a base incorporation has occurred, or if multiple incorporations occurred, and knowing what reagents were delivered before such incorporation the sequence of the DNA can be determined Magnetic Array

The present invention provides magnetic arrays and methods of using the magnetic arrays for polynucleotide amplification and sequence analysis, thereby providing fast, convenient, and/or low-cost DNA sequencing. The magnetic array may comprise a substrate having a plurality of magnetic regions thereon to form the array, the localized magnetic fields being sufficient for trapping magnetic beads as described herein. The localized magnetic features may be formed from a permanent magnetic material (e.g., ferromagnetic), or may be non-permanent and magnetized (and demagnetized) by an electric field.

The array may be formed from any of the known substrate materials, as described, for example, in U.S. Pat. No. 7,682, 837, which is hereby incorporated by reference. In certain embodiments, the substrate material may include at least one of silicon, silicon-based material, glass, modified or functionalized glass, plastic, metal, ceramic plastics or a combination thereof. The substrate is generally a non-magnetic material.

The localized magnetic features may be created with permanent magnetic material (e.g., ferromagnetic), or may be non-permanent (e.g., electromagnetic-induced regions). In

certain embodiments, the plurality of localized magnetic features may be formed from a magnetic material, and each region may be a substantially uniform size and shape, to thereby form an array (e.g., a grid-like pattern), and may thus form a plurality or array of localized magnetic features. In 5 other embodiments, the magnetic features may be non-uniform. In exemplary embodiments, the magnetic features may be magnetic bars, which may be formed at least in part from a magnetic material comprising, for example, aluminum, cobalt, samarium, neodymium, boron, copper, zirconium, 10 platinum, chromium, manganese, strontium, iron and/or nickel, and including alloys thereof, and may include other materials and elements. In a one embodiment, the magnetic features may be formed at least in part from an alloy of nickel and platinum (e.g., about 50%-50%) or an alloy of cobalt and 15 platinum (80% Co 20% Pt) or an alloy of cobalt, chromium and platinum. The localized magnetic fields may be contained within wells on the substrate, or alternatively, the substrate does not contain wells, allowing amplification or sequencing reagents to flow freely over the substrate surface, thereby 20 simplifying the sequential addition and control of reagents (e.g., sequential addition of NTPs for sequencing), which can directly improve dephasing and signal to noise ratio for long read sequencing.

In a further embodiment, well structures, depressions, pro- 25 trusions, or other means of limiting the motion of a bead or particle may be utilized in combination with localized magnetic fields to retain a bead or particle in a fixed position, forming a bead capture feature.

Various methods of fabrication may be used for creating 30 the localized magnetic features (e.g., magnetic bars). In certain embodiments, the localized magnetic features or bars have sharp edges, which may be fabricated by photolithography and then sputtering of the magnetic layer. In other embodiments, the localized magnetic features (e.g., bars) 35 may be fabricated by sputtering/coating of a magnetic layer, followed by photolithography, and then ion-milling to etch off excess material and creating sharp or specific angle edges. In some embodiments, the fabrication may utilize multi-layer resist lithography.

The localized magnetic features may be configured to be in a single domain state. The localized magnetic features may be fabricated with a number of layers, alternating between a ferromagnetic material and an intermediate layer of another material such as chromium, in order to improve the coercivity 45 of the multilayer magnetic structure. In addition to the alternating layers, there may be a seed layer and a protective layer of a material such as Tantalum, MgO or other appropriate materials as known in the art. There may be a number of alternating layers, for instance 2 to 40 layers, for example, 2 50 to 4 layers, 5 to 10 layers, 10 to 16 layers, or 16 to 30 layers, or 32 layers or more. The grain orientation may be parallel to the long axis on the localized magnetic features. The thickness of the layers may vary from 5 nm to 15 nm or more for each layer.

In some embodiments, the localized magnetic features may be rectangular prisms, with a length of about 20 microns, with a width of one to 2 microns, and gaps for holding a bead or particle may be 2 to 3.5 microns when the diameter of the bead is 4.5 microns. The lengths, widths, and gaps may all be 60 scaled up or down as appropriate for a larger or smaller bead or particle. For example, for a 2.8 micron bead, the localized magnetic features may have a length of 10 microns, a width of 1 to 2 microns, and a gap for holding said bead or particle of from 1.25 to 2.5 microns.

The array may be a high density or low density array. The arrays generally contain at least 100 magnetic regions per

8

The localized magnetic fields may be sufficient for trapping (by magnetic force) magnetic particles having a size of 50 µm or less. In certain embodiments, the localized magnetic fields may be sufficient for trapping magnetic particles having a size of 20 µm or less, 5 µm or less, 500 nm or less, or 50 nm or less. In certain embodiments, the beads have a diameter of from about 3 µm to about 5 µm, and in other embodiments the beads have a diameter from about 0.5 µm to 3 µm. The magnetic particles may be ferromagnetic, paramagnetic, or superparamagnetic, and suitable materials are well known, as described in U.S. Pat. No. 7,682,837. The beads may be moved into the array by flow, for example, via a channel having a height of from about 5 to 50 μ m, such as about 15 μ m. The width of the channel may vary, but in some embodiments may be from about 500 μm to 1 mm, such as about 800 μm. In other embodiments the channel width may be from 1 mm to 20 mm or more. In some embodiments the channel may have supporting posts or ribs to better control the height. In other embodiments, parallel channels may be utilized, either to accommodate more array positions for a single sample, or to accommodate multiple samples.

In some embodiments of the current invention, wherein magnetic beads or particles are utilized without a magnetic array, said magnetic beads may self assemble into a monolayer with uniform spacing. In other embodiments the self assembling beads or particles may be nonmagnetic. In some embodiments depressions associated with the sensors can facilitate a one to one correspondence and may result in better alignment between the beads and the sensors permitting better detection. Slow translation or movement of the beads may be appropriate after conditions have been caused to be appropriate for binding, in order to enable alignment of the beads with the sensors. Such translation or movement may occur in 40 multiple dimensions, which may include x, y, theta, and may have varying movements in time and distance to accommodate the spacing of the sensors and the size of the beads. In other embodiments, a circular fluidic movement may be used to ensure high rates of bead loading.

In designs with deep wells beads or particles may not be adequately accessible to fluid flow. In some embodiments, the beads or particles are more accessible to fluid flow, as they may protrude above the surface of the device. As a result, the beads may respond more quickly to introduction of reagents, permitting better, quicker and more efficient washes and reactions.

FIG. 1A schematically illustrates the addition of beads 102 to a magnetic array 104A. FIG. 1B schematically illustrates the positioning of said beads in a one to one correspondence with the retention regions on the array 104B. FIG. 1C shows the sensor array after the beads have been washed off ready for use for the next sample.

FIG. 1D illustrates various embodiments of the current invention wherein the magnetic, paramagnetic, non magnetic particles or a combination thereof may be of shapes other than spherical for use with either a sensor array 104C with magnetic retention, a sensor array with electrical confinement not shown or a sensor array with self assembled particles 104D. In one embodiment said particles may be substantially planar. The substantially planar particles may be round, rectangular 106A, star shaped, hexagonal 106B, or in another shape. In other embodiments, the particle may be dendritic including a

dendritic structure formed by a self assembled 3D DNA network, enlarging the surface area of said particle. Said dendritic particle may be generally spherical, substantially planar, oval, or any other shape. In some embodiments, primers may be attached said dendritic particles. In other embodi- 5 ments DNA nanoballs may be attached to dendritic particles or other types of particles or beads. In yet other embodiments, said particle may be porous or partially porous; if said particle is porous or partially porous, the pore size may be of sufficient size as to permit free movement of DNA, polymerase, dNTPs and other moieties necessary for primer extension sequencing or other applications as appropriate In all places where the term bead is utilized, it may be assumed that it may be of any shape as described herein.

FIGS. 2A and 2B are micrographs of localized magnetic 15 arrays filled with magnetic beads, as described in various embodiments herein, illustrating the routinely high occupancy level achievable and illustrating a further embodiment of the current invention, wherein a single magnetic or paramagnetic bead may be held in place in a single position in the 20 magnetic array. Said beads may be sized such that there may be sufficient room for only one bead over each sensor, thus providing for a one to one correspondence between array positions and beads. Although there may be room for only one between beads when the beads may be aligned in proximity to the sensors, resulting in reduced cross-talk between sensors. For example, a set of beads may be 10 microns in diameter located over sensors which may be 8 microns across, and the sensors may be spaced 15 microns apart, resulting in a 5 30 micron space between the beads. The size of the sensors may be larger than the beads, if there is insufficient room for two beads to be retained above the sensor. The size of the beads, sensors, and spacing can vary. In other embodiments, beads may be greater in size than 10 microns, such as 15 microns, 20 35 microns, 25 microns, or larger. In further embodiments the beads may be smaller than 10 microns, such as 5 microns, 3 microns, 2 microns, 1 micron, or less than one micron. The sensors may be sized to align with the size of the beads, and thus may be larger, or smaller in size than 8 microns across, 40 potentially ranging from less than one micron, to 1, 2, 3, 5, 10, 15, or more microns across. The spacing between the sensors may also be greater than 15 microns, or may be less than 15 microns; the sensor spacing may range from less than one micron, to 1, 2, 3, 5, 10, 15, 20, 25 or more microns between 45 sensors. The sensors can be arranged in a square, rectangular, hexagonal or other 2-D pattern. Although described herein primarily for DNA applications, including amplification, real-time PCR, sequencing, digital PCR, DNA hybridization probe array, the magnetic arrays may be utilized for other 50 applications, such as applications or methods utilizing and or detecting antibodies or other proteins.

In some embodiments with 4.5 um diameter magnetic beads a flow rate of 0.07-0.14 mm/sec may be desirable for bead loading to allow capture by the localized magnetic 55 fields. A flow rate of 1.4-4.2 mm/sec may be desirable for reagent delivery to prevent dislodging of the magnetic beads. A flow rate of >5.6 mm/sec may be desirable for bead removal. In other embodiments the use of air bubbles can be used to remove the beads. Larger and smaller beads may be 60 used with higher and lower flow rates although the relationship may not be linear.

Other Reuse Methods

After a set of sequencing cycles has been completed, the primers may be removed and replaced. Buffer conditions can 65 be changed to weaken a biotin streptavidin bond, such as high concentrations of GuHCl at low pH; alternatively the tem10

perature can be raised to over 70 C to break the biotin streptavidin bond. Lower temperatures may also be used with low ion strength buffers, such as buffers with micro molar salt concentrations. Combinations of the above may also be utilized, such as higher temperatures and low ionic strength buffers. Thiol bonds can likewise be broken at elevated temperatures. Aggressive means may be utilized, as damage to the polymerase and DNA may be no longer consequential, as the sequencing reaction has already been completed. In one embodiment, organic reagents may be utilized to break the binding between the extended primer and the surface, such as a covalent binding. After the extended primers have been removed, new primers may be flowed into the volume above the sensors, enabling the device to be used again for another set of sequencing cycles on another set of DNA samples. Said new primers may be bound in a single phase liquid. Said new primers may also have additional reagents included in the fluid containing said primers which assist binding or associating of the primers to the sensors. The new primers may be utilized in an amplification reaction to generate a new clonal population for subsequent sequence analysis, as described herein. Said amplification may be PCR or isothermal amplification.

In a further embodiment, an amplification or sequencing bead over each sensor, there can be an additional distance 25 array may be reused by the removal of beads. Said removal may be done, for example, by the application of an external magnet field, which may result from the movement of a permanent magnet or the activation of an electro magnet, to pull, move or dislodge beads or particles from wherein they are held in said amplification or sequencing array.

> In an alternative embodiment, wherein said beads or particles are held in place with a Biotin Streptavidin binding, thiol binding, DNA, LNA, PNA, or other nucleic analog hybridization, or the like, the release of said binding may be achieved by changing the temperature and or fluidic environment proximate the bead or particle, so as to reversibly break the binding, so that new beads or particles may be subsequently bound or associated in the amplification or sequencing array.

Sequencing

FIGS. 3 and 4 are schematic illustrations of the reaction involved in incorporating nucleotides into a growing DNA strand, showing the release of pyrophosphate and concomitant increase in pH. As described herein, the integrated sequencing platform may include an electronic sensing subsystem configured to electronically detect the change in pH or charge concentration or mobility to "electrically sequence" the DNA. In other embodiments, an electronic sensing subsystem can be configured to electronically detect the change in temperature resulting from this reaction to "electrically sequence" the DNA.

FIG. 5A depicts two sets of beads, one with clonal sets of DNA bound or attached thereto, and a set without clonal sets of DNA bound or attached thereto. This system permits utilization of the beads without clonal DNA bound or associated thereto to be used as a reference, removing offset, nucleotide and other reagent charge, temperature, fluidic flow and pressure, buffer concentration changes and other systematic variables to be removed. As shown in FIG. 5A, in schematic system 510, said removal of system variables may be done at least in hardware, using an analog subtraction. In other embodiments, the removal of systematic variables may be performed is in software and or external hardware. In yet other embodiments, a combination of local hardware and software and or external hardware may be utilized. FIG. 5B depicts resultant data, wherein most putative incorporation reactions result in signal levels indicative that a reaction did

not occur, while some putative incorporation reactions result in signal levels indicative of a single incorporation event, and other putative incorporation reactions result in signal levels indicative of multiple incorporation events in a homopolymer region of the clonal DNA.

In a further embodiment, an electronic sensing subsystem may detect a change in conductivity, either in a bulk solution, across the surface of the sensor (either from moieties bound to the sensor or from moieties within the Debye length of the surface of the sensor), across the surface of a bead or particle (either from moieties bound to the bead or particle or from moieties within the Debye length of the surface of the bead or particle), or a combination thereof. In a yet further embodiment, an electronic sensing subsystem may detect a change in charge near or on the surface of the sensor, near or on the surface of a bead or particle. For example, the electronic sensing subsystem may detect charge changes within the Debye length of the surface of the sensor, or bead or particle, or of moieties bound to the surface or bead or particle.

FIG. 6 includes a schematic illustration of a nanosensor 604 and a series of nanosensors 610 associated with the microfluidic channels in electrical communication with the sequencing system. The nanosensors may have clonal DNA 602 bound or associated directly thereto, and may have elec- 25 trodes or magnetic elements 608 associated with each nanosensor. In other embodiments the sensor may detect changes in the charge of the clonal DNA on the bead, changes in the counter ions associated with said clonal DNA, or byproducts which result from an incorporation. The nanosensor 604 may further include a signal amplifier 606 for on-chip signal amplification. The nanosensors 604 may further include any of the known insulator materials, such as SiO₂, Al₂O³, SiN, and TaO₂In certain embodiments, the nanosensors may comprise coaxial and/or parallel conductive layers, 35 separated by an insulator layer. The conductive layers may be formed from any suitable material, such as gold, platinum, aluminum, carbon, or polysilicon.

The (magnetic) beads and DNA fragments may be conveyed into the sequencing system. As shown in FIG. 7, the 40 sequencing system may include a series of nanosensors 708 in communication with the microfluidic channels defined within the sequencing system. The beads or particles 702 may be positioned over said sensors 708 by magnetic or electrode elements 710, which may form localized magnetic fields in 45 some embodiments and may form localized electric fields in other embodiments, wherein both the sensors 708 and magnetic elements may be configured in association with a substrate 712. The beads or particles 702 may have clonal DNA 704 bound or associated thereto. Reagents, which may 50 include nucleotides, primers, magnesium and polymerase 706 may then be provided to initiate a sequencing reaction. In other embodiments, when magnetic or electrode elements 710 are magnetic elements, they may be either permanent magnetic elements or electromagnetic elements.

In other aspects, the invention provides a method for sequencing a polynucleotide, using a magnetic array, forming an array of localized magnetic features as described herein. The method comprises contacting the magnetic array with a plurality of magnetic beads, the magnetic beads each having 60 attached thereto a clonally amplified DNA segment, which may be single stranded, partially double stranded or double stranded. Whether single stranded, partially double stranded, or double stranded, the template DNA may be converted to single-stranded DNA by denaturation and a sequencing 65 primer may be hybridized to the single-stranded DNA to prepare for sequencing.

12

After base-calling, the recorded sequence at each location on the array may be assembled. For example, by using a shot-gun sequencing method, wherein the identities of the fragments at each position of the array may be unknown, or a polynucleotide sequence may be assembled based upon a reference sequence (e.g., a wild-type sequence).

The clonal DNA sequences may each have a single-stranded region, acting as a template for nucleotide incorporation. The single stranded region may be at least 10 bases in length, or in some embodiments, may be at least 300 bases in length, or in other embodiments, at least 1 kb in length. The invention thereby provides for long, accurate, and cost effective reads. There may be more than one amplified populations of polynucleotides in one clonal population as defined herein, wherein the different amplified populations of polynucleotides may have different primers, so that separate sequencing reactions may be performed for each of the amplified populations within a single clonal population.

In another aspect, the magnetic array comprises an adjacent nanosensor for determining a change in pH of a microenvironment, the microenvironment including the environment in the vicinity of the bead held by the localized magnetic field. In this aspect, the microarray may be useful for electronic sequencing of DNA. Methods for sequencing by detecting a change in pH are generally described in U.S. Patent Publication No. 2008/0166727, which is hereby incorporated by reference in its entirety. Alternative methods of detecting incorporation of polynucleotides may be used, including thermal sequencing (e.g., as described in U.S. Patent Publication No. 2008/0166727), detection of charge concentration, mobility of charged species and byproducts, and known optical detection methods.

The magnetic array comprises a substrate having a plurality of localized magnetic features thereon to form the array, the localized magnetic fields being sufficient for trapping magnetic beads as described herein. The localized magnetic features may be formed from a permanent magnetic material (e.g., ferromagnetic), or may be nonpermanent and magnetized (and demagnetized) by an electric field.

In other embodiment, an electric field may be used to hold or retain a bead or particle in a location as will be described later herein.

Detector

A magnetic or paramagnetic bead or particle may be held in place over or proximate a sensing region by a magnetic array, forming an array of localized magnetic fields. Retained magnetic or paramagnetic beads may have monoclonal populations of DNA. Said beads may be sized such that there may be sufficient room for only one bead over each sensor, thus providing for a one to one correspondence between sensors and beads. Although there may be room for only one bead over each sensor, there can be an additional distance between beads when the beads may be aligned over the sensors, resulting in reduced cross-talk between sensors.

The magnetic sequencing array comprises a plurality of nanosensors, with at least one or two nanosensors in the vicinity (microenvironment) of each of the localized magnetic fields. The nanosensors have a high sensitivity for detecting slight changes in pH or charge concentration in each microenvironment (e.g., the vicinity of each localized magnetic field). For example, an array may comprise 1000 nanosensors or more, 2000 nanosensors or more, 4000 nanosensors or more, 10,000 nanosensors or more, 10,000 nanosensors or more. 10,000,000 nanosensors or more. The nanosensors may comprise measuring electrodes having two terminals, sufficient to determine an

increase in the ionic (H⁺) concentration, or an increase in the counter ions associated with DNA in the corresponding microenvironment or the occurrence of the polymerization reaction.

The nanosensors may include at least one pair of measuring electrodes having positive and negative terminals, sufficiently spaced apart (e.g., a spacing of between 20 and 30 nm) and constructed to detect a change in the ionic concentration of the corresponding microenvironment. In other embodiments the spacing between the electrodes can be 100 nm to 500 nm or 1000 nm to 5000 nm. More particularly, the nanosensor can detect a change in the impedance of the fluid within the microenvironment caused by a change in the ionic concentration of the corresponding microenvironment as a result on an incorporation event or a chemical reaction of the biological material on the beads and another material. In an alternative embodiment, the sensor can be a resistive semiconductor element as described in U.S. Provisional patent Application No. 61/389,590 entitled "Biosensor Devices, 20 Systems and Methods Therefore." In yet another embodiment, the nanosensor may be a ChemFET or ISFET, as described in U.S. Pat. No. 7,695,907 "Gene detection fieldeffect device and method of analyzing gene polymorphism therewith", U.S. Pat. No. 7,948,015 entitled "Methods and 25 Apparatus for Measuring Analytes Using Large Scale FET Arrays," U.S. patent application No. 2011/0171655 entitled "pH Measurement for Sequencing of DNA" and U.S. patent application Ser. No. 13/118,044 entitled "Nano-Sensor Array," each of which is hereby incorporated by reference in its entirety. Whenever the term nanosensor is utilized herein, it may be considered to be a set of electrodes as described above, or may be a resistive semiconductor element, or may be an ISFET or ChemFET or combination of the abovementioned sensors.

In some embodiments of the current invention, a combination of different sensing methods may be utilized, for example, a NanoNeedle and a NanoBridge, or an ISFET and a NanoNeedle. In some embodiments, the different sensors may sense different properties associated with the target moieties. For example, a NanoNeedle may detect the conductivity of moieties bound or associated with the target moieties, while a NanoBridge may detect charge bound or associated with the target moieties.

FIG. 8A shows a photomicrograph of an array of nanosensors, and a zoomed in view of a single nanosensor 802. Impedance measurements may be used by such a nanosensor for detecting incorporated nucleotides. The impedance measurement detects the release of H+ ion pyrophospate or local 50 change in charge resulting from the polymerization reaction. Generally, the frequency of operation may be selected for maximum change in the impedance over the course of the reaction relative to the impedance at the beginning of the reaction. For example, for some geometries, the frequency 55 may be around 0.1 to 9 KHz. In alternative geometries, the frequency may be 10 KHz or greater. In some embodiments, the nanosensor may be implemented with a single pair of electrodes with or without a pH-sensitive material (e.g., redox sensitive material) to detect the H+ ion release or pH change 60 of the reaction. The impedance measurement may be taken, as an example, by determining the current while sweeping from -A to +A volt or the reverse, with periodic sub-signals. A pulse wave with smaller amplitude than A, and a frequency of about 25 Hz or above, can be applied. A measurement of the 65 current during a voltage sweep may indicate a change of pH in the solution proximate the nanosensor. FIG. 8B shows a

14

schematic illustration of an array of said nanosensors **802**, wherein an on chip amplifier **804** may be associated with each nanosensor

FIG. 9 is a schematic illustration of an array of nanosensors 902 within the sequencing system. The nanosensor may comprise two electrodes 904, separated by a dielectric 906. Although shown in FIG. 9 as including an array of nanosensors, in other embodiments, the measurement can be done with a single electrode pair to detect the change of ionic construction or pH through impedance, charge, or current measurement.

The system may be calibrated for sequence analysis as follows. To reduce the common noise and signals from various environmental sources (e.g., thermal noise, mixing or fluidic noise, or the effect of nucleotide charges or other reagents), one or a plurality of beads(s) without DNA may be located in a similar environment as the DNA-coated beads. A differential measurement between the recorded signals from the two sensors (detecting the microenvironment of a DNAcoated-bead and bead-without-DNA or sensor without bead) dramatically reduces the noise, and results in an improved signal-to-noise ratio during detection. In some embodiments multiple local reference sensors can be combined to create a local average reference. In other embodiments magnetic features can be left off creating sensor positions with no beads. In some embodiments, the differential measurement may be done by comparing a neighboring DNA bead with no reaction in a cycle with the bead of interest for the same cycle. In other embodiments, the neighboring beads for differential measurement may be chosen from the region that receive the fluidic flow at substantially the same time, or beads without DNA or with DNA and without a reaction in that cycle. In other embodiments, averaging of the background signal over more than a single cycle may be used. Differential measurement of the sensor with another sensor which is shielded from contact or interaction with the fluid or target moieties.

In some embodiments, the integrated sequencing platform can produce a better signal to noise ratio, reduce the noise level from the proton (H+ion) and OH—effect in sequencing detection and/or produce better isolation in virtual wells, than may be currently possible using known systems and methods. More particularly, in some embodiments, systems and methods can employ a buffer media configured to improve the performance, as stated above. The buffer can have different mobility and diffusion coefficients for H+ (proton) ions than the coefficients would be in water. The buffer can also have different changes in the coefficients for H+ and OH—. In some embodiments, a buffer media can be a material very similar to water, but with different mobility of H+, such as Deuterium oxide (D₂O or heavy water) or any common material having this functionality. The difference in mobility can slow the movement of H+ ion released in polymerization reaction. In another aspect, the buffer media can include material having different mobility for H+ ions and/or different materials e.g. DNA, nucleotides, primers or other moieties, and can be a gel-type material. A gel-type material would result in different mobility and diffusion for H+ ions released within the gel-type material, and facilitates easier detection, resulting to a better signal to noise ratio.

To calibrate the system for sequencing, and to ensure that the recorded signals from individual sensors may be appropriate and correct, a common sequence of nucleotides may be embedded in all template DNA strands being sequenced. This common sequence may be introduced during the amplification stage by design of the amplification primer. For example, a sequence of AATCGA may be incorporated at the front end of all sequences, and may be utilized to calibrate the system,

allowing known readouts of each of the nucleotide incorporations, also permitting calibration of a single base incorporation as opposed to a two or more base incorporation. Any combination of bases could be utilized, which could utilize all four of the bases, three of the bases, two of the bases, or a single base, and could include single base incorporations, two base incorporation, or any number of bases, up to and including eight base incorporations or more. Different primers may also be used as a means for encoding different samples.

Electrical Confinement and Retention

In one embodiment, a magnetic array may comprise electrodes positioned to create an electric field around each of the localized magnetic fields, to thereby concentrate template DNA, polynucleotides and dNTPs around the localized magnetic fields (e.g., by electroosmostic, electrophoretic or dielectrophoresis force) to thereby enhance a polynucleotide amplification or polymerization reaction. The electric fields can create isolation between the regions of the array during the PCR or sequencing process, conduct DNA strands and/or nucleotides or other charged molecules toward the beads for 20 clonal PCR, and/or conduct nucleotides toward the DNAcoated beads for sequencing. For example, electrodes may be positioned under the bead capture positions and in several positions surrounding the bead capture regions, such as in a circular or square arrangement, so as to enhance the polymer- 25 ization reaction. The magnetic array for sequencing analysis may be created on a non-magnetic substrate as described. The read-out circuitry and on-chip amplifiers, which may be in pixelated structure, may be implemented above the substrate. Subsequently, the individual nanosensors may be fabricated, 30 which may be in contact, directly or indirectly, with the microenvironment of the reaction as shown in FIG. 10. The magnetic bar array 1006 generates localized magnetic fields to associate the beads in the proximity of the sensors 1008. Optional associated amplifiers 1004 may be fabricated above 35 or below the sensor layer as shown in FIG. 10 as part of an integrated device 1002. Microfluidic channels may be embedded in the structure. The chip may be operably connected with a data acquisition unit. In other embodiments, bead retention in bead capture features may occur utilizing a 40 localized electrical field. In some embodiment the bead or particles can be nonmagnetic. Yet further embodiments may comprise electrodes positioned to create an electric field around each of the bead capture feature, sensors or other desired locations, to thereby concentrate template DNA, 45 polynucleotides and dNTPs (e.g., by electroosmostic, electrophoretic or dielectrophoresis force) to thereby enhance a polynucleotide amplification or polymerization reaction. The electric fields can create isolation between the regions of the array during the PCR or sequencing process, conduct DNA 50 strands and/or nucleotides or other charged molecules toward the beads for clonal PCR, and/or conduct nucleotides toward the DNA-coated beads for sequencing.

FIG. 11 schematically illustrates some of the forces which combine to localize the charged moieties with lower diffusion 55 constants in a desired volume, including the electrophoretic flow which may result from an impressed electric field, frictional force, electrostatic force, and electrophoretic force. The schematic 1108 shows a voltage source 1118 generating a voltage impressed on the electrodes 1106, to generate a 60 localized electric field.

The localized electric field may comprise AC and or DC components, and may utilize non-sinusoidal waveforms. Said non-sinusoidal waveforms may comprise triangle waves, square waves, or waves of any shape. Said non-sinusoidal 65 waveforms may comprise a "dead spot" in, for example the peak of a sinusoidal waveform, in order to allow hybridiza-

16

tion binding, enzymatic binding, other binding, and enzymatic activities to occur without the presence of a potentially interfering electric field. Other "dead spots" could be utilized for example, in a square wave, wherein the voltage could be raised to level of A volts for a period of time, and then be reduced to zero volts for a period of time. The voltage could then be raised to A volts again, followed by an amplitude of negative A volts. The "dead spot" need not be zero volts, but can be reduced sufficiently so that a desired interaction between different moieties influenced by the electric field may occur. The result of localized electric field on the charged molecule concentration 1109 shows the substantial gradient which results from the electric field and may provide substantial isolation

Although described herein primarily for DNA applications, electrical confinement as described above may be utilized for other applications, such as applications or methods utilizing and or detecting antibodies or other proteins or chemical metabolites. In some embodiments, other reactions other than sequencing or amplification may be performed in a set of virtual wells. For practical usage in such an application, the moieties which need to be isolated need to be charged or associated with other charged moieties.

FIG. 12 shows electric potential at a horizontal cross line 1209 above the electrodes from a simulation 1208 which results from an electrical field being applied to the electrodes 1206. The stream line electric field 1202 and electrical potential due to the DC voltage which may be used for capturing charged moieties, including DNA amplicons near beads and preventing them from migrating toward the next bead. This simulation was performed for dNTP migration.

In one embodiment of the current invention, the magnetic bar and electrode array provides for an emulsion-free method of clonally amplifying DNA fragments on magnetic beads, by isolating regions of the array by magnetic and or electric fields. Clonal amplification on beads has been generally described in U.S. Pat. No. 7,323,305, which is hereby incorporated by reference in its entirety. The invention may employ bridge amplification, which immobilizes the DNA strands on a surface of a bead, particle or sensor during amplification, thereby further preventing diffusion of DNA strands to other beads, particles, or sensors.

In an exemplary method for amplifying DNA fragments, magnetic beads may be injected onto the magnetic bar array having electrodes forming an electric field. DNA strand templates (double-stranded or single stranded) may be injected into the chamber to go over the beads in a concentration targeted for a desired DNA-strand per bead distribution, thereby allowing for clonal amplification. In certain embodiments, to insure that polyclonal regions are not generated, the concentration of input DNA needs to be low enough that most sensor regions have one or zero sample DNA molecules. dNTPs and DNA polymerase may then be injected into the chamber, and may be concentrated around the beads by virtue of an electric field as described. DNA primers for amplification may be provided at any step, such as when adding dNTPs and/or polymerase, or provided with the DNA templates. The DNA fragments immobilized on the beads may be amplified by PCR or isothermal amplification. Where double stranded DNA is the starting material, the first step of the amplification process creates single-stranded templates by "melting" the double stranded fragments, followed by primer annealing and extension steps, and repeated heating cooling cycles if PCR is utilized, or by a continuous controlled temperature for an isothermal amplification. FIG. 13 shows a fluorescent photo-

micrograph of clonal beads with double stranded DNA held in an array as described herein.

During the amplification process, dielectrophoresis forces may also aid in preventing cross contamination between different sensor regions undergoing amplification by retaining 5 amplicons. In the embodiment illustrated in FIG. 15 the additional electrodes are shown as having the same voltage relative to voltage level of the sensors. In an alternative embodiment as shown in FIG. 14 electrodes on either side of a sensor may have voltages of opposite sign or the same sign with 10 different values relative to each other.

In addition, a gel-type material can act as an isolating material in and or between different regions during amplification or sequencing with a magnetic array. The use of such a gel-type buffer media can result in minimal diffusion of DNA 15 strands from one localized magnetic field to the neighbor (or adjacent) localized magnetic field, because the nucleotides (dNTPs), Mg2+ and other materials may be introduced during cyclic injection and can be transported through the geltype or spongy media. The gel-type material can be any 20 suitable material, such as agarose or acrylamide or other cross linking materials, in which cross linking may be initiated through physical or chemical triggers. One example of such triggers is a change of temperature (as a physical trigger), or the addition of a substance (to produce a chemical change to 25 the material to make the media into the gel-type phase).

A "gel-like" or "spongy" material can also help confine the DNA strands in the volume near the beads, or help confine the DNA strands in or near the localized magnetic fields and/or reduce the diffusion of the polynucleotides. In such embodiments, the nucleotides and other materials may be allowed to diffuse more readily, but DNA strands, particularly sample or amplicon fragments may be impeded from freely diffusing.

In some embodiments, this method may reduce the diffusion of the DNA in the amplification portion of the system. 35

FIG. 14 depicts an alternative embodiment, wherein a clonal population may be generated in the area, or on individual sensors 1402 in a sensor array. The sensors may be NanoNeedles or NanoBridges or other sensors to detect the event of polymerization. In one embodiment, primers 1404 40 may be preferentially bound, associated with or attached to the surface of the sensors. Said primers 1404 may be preferentially attached as a result of a difference in materials, wherein the material of the sensor may be more advantageous for attachment then the areas between the sensors of the 45 sensor array. In an alternative embodiment, a mask may be applied to areas between the sensors of the sensor array, and a surface modification may then be performed. Subsequently, the mask may be removed; leaving an area between the sensors of the sensor array wherein the surface modification has 50 not been performed. The surface modification may include attachment of biotin, applying a layer of gold and various other methods as are known in the art.

Primers 1404 may then be preferentially applied to the areas on the surfaces of the sensors 1402 in the sensor array. 55 In one embodiment, the primers could be attached as a result of a biotin streptavidin binding, wherein the biotin or streptavidin may be attached to the 5' end of the primers. In another embodiment, a thiol group may be attached to the 5' end of the primers, which can then bind to the gold layer previously 60 applied above the sensor, forming an Au—S bond. If a PCR reaction is desired, the primers may be modified with DTPA such that two thiol gold bonds may be formed, preventing the dissolution which may otherwise occur from the 60 to 95 C temperatures routinely used in PCR. Target DNA 1406 may 65 be concentrated in the area of the primers 1404 by electric fields 1406 generated by electrodes 1408A and 1408B. Prim-

18

ers, dNTPs 1410, and polymerase 1408 may be introduced and optionally concentrated by electric fields generated by electrodes 1408A and 1408B.

In some embodiments, amplification may be a solid phase amplification, wherein one primer may be on the surface of the bead, and a second primer may be in solution. In other embodiments, the amplification may be solid phase wherein all primers are on the bead, or the amplification may be performed whereby both primers are present in solution, and one primer or both primers may be also present on the bead. In a further embodiment, the amplification may be performed whereby one primer is present in solution, and one primer or both primers are also present on the bead.

The electrode configuration may take various different forms, including a substantially planar electrode on one or both major planes of the flow cell, or there may be an electrode on the surface opposite the beads, and a set of smaller electrodes associated with each sensor, or bead capture region FIG. 15 schematically illustrates one embodiment, wherein a set of sensors 1502 may be located associated with electrode structures 1504 and 1506, wherein the electrode structure may have an electrode 1504 located in immediate proximity to the bead capture feature, and a larger electrode structure 1506 may encircle the bead capture feature and the smaller electrode 1504. The bead capture feature may be in proximity to the sensor active area when the embodiment used for sequencing or detection. The larger electrode is illustrated as a circle, but it may me a square, a rectangle, an oval or other shape, and need not completely encircle the smaller electrode

The substantially planar structure may include depressions or wells for better alignment or field focusing, or pedestals for better fluid flow characteristics.

Prior to amplification the beads may be associated, in some embodiments, with a single DNA fragment in order to create monoclonal beads. Typically the DNA concentration may be determined and then the DNA may be introduced to beads in a dilute form so that on average less than 1 fragment may bind to each bead. Many beads have zero DNA fragments, fewer have a single fragment and a small number have 2 or more fragments. The steps needed for quantitation often require a separate instrument and separate processing. Frequently quantitation may be done utilizing real time PCR, or determination of the absorption at 260 nm.

If three or more electrodes are utilized, different voltages may be utilized for any set of the electrodes.

A polymer may be utilized in conjunction with an AC field which has one phase with a higher voltage and shorter duration in order to provide directed mobility of the target molecules.

In one embodiment the sample could be made very dilute and/or a small volume of sample reagent may be utilized and loaded onto beads. DNA would bind to some of the beads and then be amplified in the virtual wells creating beads with DNA. The sequencing primer could be made shorter than the complement ligated to the sample DNA. Since the sequence is known, the correct dNTPs could be added and detected. In one embodiment multiple dNPTs could be simultaneously added. For example, if all dNTPs are added the polymerase would extend to the end of the fragment generating a large signal. Said large signal could be generated as a part of the amplification process. This would allow the detection and counting of the number of beads that have DNA even if the beads had minimal amplification. Knowing how many beads have signal would allow calculation of the proper dilution to

generate the ideal number of monoclonal beads. The signal may be electrical, optical or any other type of the detection signal known in then art.

In some embodiments, electric confinement of amplicons, polymerase or other moieties may be utilized with a device which does not have any physical well structure. In other embodiments, the device may be a substantially planar surface, wherein depressions or protrusions exist. In yet other embodiments, the device may have well structures.

Electrical Concentration

As illustrated in FIGS. 6 and 12, the sensor array may be provided with an additional array of electrodes, which may be utilized to perform dielectrophoretic concentration. Dielectrophoretic concentration may be initially performed to attract sample DNA 1206 dNTPs 1210, primers, and polymerase 1208, to each sensor or amplification region, permitting lower concentrations of each said moiety to be utilized. Amplification can then commence in the region of each sensor where a sample DNA molecule may be located. The electric field generated virtual well can prevent amplicons from leaving one virtual well and traveling to another virtual well, generating cross contamination. In a similar manner, the fields used to localize the amplicons may also concentrate the amplicons, primers, and polymerase to the region of the sensor or amplification region.

In another embodiment the sample may be concentrated in the amplification region using the existing electrodes of the emulsion free nano-well. In one embodiment electrodes may be established on a single plane. In another embodiment 30 electrodes may be added to a second plane parallel to the plane of the virtual wells. In other embodiments mixtures of AC and or DC voltage inputs are anticipated.

In another embodiment dielectrophoresis could be used to concentrate DNA. During or after concentration the electrical 35 current could be measured to determine the DNA concentration. In another embodiment the concentrated DNA could be quantitated by the use of intercalating dyes as described below.

The isolating field electrodes may also be utilized for concentration. In some embodiments the same electrodes and field may be utilized. In other embodiments, fewer or more electrodes may be utilized to generate the concentration field, relative to those used for generating an isolating field.

Concentration may be utilized to maximize utilization of 45 sample, for example, directing or pulling DNA sample to virtual wells for subsequent amplification. Concentration may also be utilized to direct or pull polymerase to a virtual well for amplification, or to a clonal set of DNA which may be associated with a bead or sensor, and said polymerase may be 50 utilized in a sequencing reaction. In a similar manner, other moieties such as dNTPs, primers, other enzymes, and other biological or other charged moieties may be concentrated for use in a reaction, or use in a subsequent reaction.

Significant amplification of sample DNA is often performed to ensure sufficient DNA sample is available at a high enough concentration for the desired protocol. This amplification can introduce bias and may be an additional cost in time and resources. The ability to reduce or eliminate the need to amplify the sample may be desirable. In one embodiment 60 the beads to be loaded may be enclosed in a packed bed and sample may be pumped across it. In some embodiments the sample can be pumped through the area with the beads multiple times to provide additional opportunities for the sample to bind. The high surface area to volume should allow minimal sample to be used. The beads can subsequently be moved into a flow cell whereby they may be held in place by a

20

magnetic array, and local colonies may be created on the beads by PCR or isothermal amplification.

Multiple Samples

Since many projects do not require the full use of the chip it may be desirable to load multiple samples in a single chip. In one embodiment, samples may be directed into separate zones separated by walls on the chip using valves integrated into the chip assembly. Such valves could be polydimethylsiloxane PDMS valves integrated into the fluidic path. In another embodiment, samples may be directed into separate zones separated by walls on the chip using valves separated from the chip assembly with multiple inputs on the chip assembly. In another embodiment there may be separate zones with separate inputs and outputs. In another embodiment samples may be directed into separate zones on a chip or flow cell using a local electric field. A positive field may be applied to attract DNA or DNA-coated beads to desired regions, while a negative field may be applied to repel DNA or DNA-coated beads from undesired regions. In another embodiment samples may be directed into separate zones using electromagnets to separate magnetic or paramagnetic beads. In another embodiment samples can be delivered into individual lanes using self sealing ports. Self sealing ports can include rubber septa and needles.

In another embodiment samples can be injected at different time points and new beads can be distinguished due to signal from previously empty bead locations.

In some embodiments of the current invention, as a part of the sample preparation process, "barcodes" may be associated with each sample. In this process, short oligos are added to primers, wherein each different sample utilizes a different oligo in addition to primer. The primers and barcodes are ligated to each sample as part of the library generation process. Thus during the amplification process associated with generating each colony, the primer and the short oligo are also amplified. As the association of the barcode is done as part of the library preparation process, it is possible to utilize more than one library, and thus more than one sample, in generating the clonal populations, permitting determination of which bead and colony originates with which sample, by sequencing the short oligo along with the sample sequence.

Sample separation methods can be used in conjunction with sample identifiers. For example a chip could have 4 separate channels and use 4 different barcodes to allow the simultaneous running of 16 different samples. This permits the use of shorter barcodes while still providing unambiguous sample identification.

In an alternative embodiment as shown in FIGS. 16 A-D, samples may be brought into a system which may have a magnetic array and associated sensor array. Alternatively the system may have a combined amplification and detection array, wherein each element of the array may have a sensor and a set of electrodes configured to create a virtual well. A DNA sample set 1604A which is configured to occupy only a portion of said array 1602A, may be introduced to said array 1602A, resulting in a portion of the available areas to have an associate sample. Such samples may then be detected by the sensors associated with each virtual well, resulting in an array 1602B as shown in FIG. 16B, or may be amplified and then detected. FIG. 16B also shows a photomicrograph of a partially filled magnetic array. FIG. 16C shows a further sample set 1604B, which may then be introduced to the magnetic and sensor array 1602B, resulting in a more completely filled array 1602C as shown in FIG. 16D.

Combined Electrical Confinement and Sequencing

FIG. 17 illustrates the use of the amplified regions above the sensors in the array of sensors which may be used in a

sequencing reaction. DNA sample 1702 may be brought into the array system 1710, wherein the array may be configured either with pre-localized beads, or with primers 1708 which may be attached, bound or associated with sensor regions **1710**. Polymerase **1704**, dNTPs **1706** and additional primers may be simultaneously, previously, or subsequently introduced to the array. After the amplification reaction 1712 has been completed, the volume above the sensor array may be washed, removing amplicons, polymerases, and dNTPs, resulting in locally bound associated or attached clonal sets being associate with array positions. Polymerase 1718, primers 1714, and individual dNTPs 1706 may then be flowed into the volume above the sensor array, permitting binding, incorporation, and detection of the incorporation events, resulting in the determination of the sequence of the different amplified sample DNA molecules. Polymerase 1718 used for the sequencing reaction, may be the same type of polymerase 1704 as used for the amplification reaction, or may be a different type of polymerase.

Separation of Clonal Beads

Part of FIG. 19 shows a schematic illustration of a system which may separate magnetic or paramagnetic beads with clonal DNA from magnetic or paramagnetic beads which have not had amplification product associated thereto and/or 25 have incomplete amplification and/or short clonal. The magnetic beads 1934 may then be separated such that magnetic or paramagnetic beads 1934 having a clonally amplified DNA segment bound thereto may be conveyed into the sequencing system, and magnetic or paramagnetic beads 1934 that are 30 largely devoid of amplified DNA may be conveyed to a waste chamber and/or retained within the PCR and enrichment system. The separation or "enrichment" may be produced by applying an electric field across a portion of the PCR and enrichment system to induce electrophoretic flow. Thus, the 35 magnetic or paramagnetic beads 1934 having amplified DNA, which is highly charged, may be efficiently separated from those magnetic paramagnetic beads 1934 largely devoid of amplified DNA. In this manner, the sample delivered to the sequencing system can include substantially only those beads 40 having amplified DNA with a desired length of DNA strands for sequencing. Similarly stated, the sample delivered to the sequencing system can include a percentage of clonal beads approaching 100%. The separation of clonal beads may be non-magnetic beads or any other type of the beads, with or 45 without the surface being coated with charged molecules.

When generating clonal beads a large percentage of the beads may have no DNA template. In addition others may have poor amplification. These beads do not provide useful sequencing so it may be desirable to remove these beads for 50 better efficiency. In some embodiments of the current invention an enrichment module may be used which separates the beads with no or minimal amounts of template using an electric field.

Beads fully loaded with templates have a higher charge, 55 and so may move farther in an electric field than beads with only primers or few templates. In one embodiment as shown in FIG. 18A-B this separation may be done in a flow through module 1800. A first fluidic input 1811A allows the injection of mixed beads. A second inlet 1812A allows the injection of a buffer solution without beads. A first outlet 1811B may be downstream from the first inlet 1811A. A second outlet 1812B may be downstream from the second inlet 1812A. Fluids may be brought into or out of the module through ports 1809. The fluidic system may have a substrate 1802, and a 65 channel 1810 formed in a layer of PDMS 1808 glass or other material.

22

The fluidic flow rates can be set by fluidic resistance or pumping speed such that more liquid flows in the second inlet. In one embodiment the inlet and outlet widths may be varied to create different fluidic resistances but other methods of modifying the fluidic resistance such as different length, height are anticipated. Similarly the fluidic resistance of the first outlet 1811B and second outlet can be modified so more liquid flows out the first outlet 1811B. In such a setup beads without a small velocity perpendicular to the flow may exit the first outlet port 1811B. Additional output channels can be added to facilitate separation of beads with medium levels of template.

A pair of electrodes **1813** may be provided which enable generation of an electric field perpendicular to the fluid flow such that the template loaded beads migrate out of the flow path towards second outlet **1812**B. Fluidic ports **1809** allow connection to the system plumbing.

The electrodes could be made of any electrode material compatible with electrophoresis. In some embodiments discrete metal wires may be used but metal traces are also anticipated. Metals such as platinum, platinum/iridium, gold and other noble metals or alloys are anticipated as well as corrosion resistant materials such as stainless steel. Non metal electrodes such as carbon are also anticipated.

The flow through enrichment module chamber can be constructed of non conducting materials such as molded plastic, glass, ceramic or moldable polymers such as PDMS. Fluidic components can be fused or bonded to create a flow chamber.

The voltage applied to the electrodes can be reduced or even reversed periodically if necessary should beads stick to the electrodes. The voltages used should be greater than that required for electrolysis (1.23V at 25 C at pH 7). Higher voltages and narrower gaps provide a higher field strength and more force on the beads. The voltage on the system can be calibrated by flowing beads without or with limited template and adjusting the voltage or flow rate such that these beads may not be moved far enough to enter the second outlet while beads with template may be directed into the second outlet.

Non flow-through enrichment modules are also anticipated but these may not be as easily automated as flow through systems. In one embodiment beads may be introduced to a chamber and a magnetic field or gravity pull the beads down. An electric field may be established pulling the beads with template up. In some embodiments a capture membrane or filter can be added in front of the positive electrode to facilitate concentration of the beads.

In some embodiments, beads or particles which do not have amplified DNA (clonal beads), and or beads or particles which have insufficiently amplified DNA, or beads and or beads or particles which have amplified DNA fragments which are too short, may be recycled and reused for a subsequent amplification reaction in order to generate well amplified clonal beads or particles. Beads or particles may also be recycled after said beads or particles have been utilized for sequencing. Said beads or particles may be recycled automatically within a single system.

In some embodiments, beads or particles which do not have amplified DNA may be directly reused or recycled without further processing of the beads or particles to prevent contamination from sample to sample. This may be advantageous, for example, when a single sample is utilized for several amplification reactions, rendering any cross contamination irrelevant, as the sample is in fact the same. In other embodiments, the amount of cross contamination which may result may be considered inconsequential, as the amount of cross contamination is sufficiently low.

In other embodiments, the beads may be treated to prevent cross contamination. Said treatment may, for example, comprise removal and replacement of all primers from said beads or particles wherein said primers may be associated or bound to the beads or particles using, for example, streptavidin binding, thiol binding, or the like, wherein the binding may be broken and another moiety bound. The primer which is bound to the beads or particles may be the same primer as was previously utilized, or may be a different primer, having for example, a different barcode included as part of the primer.

In other embodiments, cross contamination may be prevented by utilizing primers with an unusual nick site, wherein the primer may be nicked, washed, a splint oligo provided and the primer restored by ligation of an oligo wherein the original sequence, or another desired sequence for the oligo is 15 regenerated or generated.

Integrated System

FIG. 19 is a schematic illustration of the integrated sequencing platform. The integrated sequencing platform may include a DNA extraction system, a library construction 20 system, an amplification system an enrichment system, and a sequencing system (which may include the electrical detection system or "sensing unit" described herein). Although shown schematically as separate systems, the integrated sequencing platform can include all of these systems within a 25 single microfluidic/microelectronic device (or "chip"). Each of the systems is described in more detail below.

The DNA extraction system includes an inlet chamber 1910 for receiving the biological sample (e.g. blood) to be analyzed. The inlet chamber can include a solution to pro- 30 mote lysing of the cells contained within the biological sample. Such solutions are well known in the art and are typically called lysis buffers. In some embodiments, the lysis solution can be injected into the inlet chamber and mixed with the biological sample. The DNA may be extracted from the 35 biological sample via an on-chip extraction element 1920. The extraction element 1920 can be disposed within a flow channel of the microfluidic device, and includes a filter media constructed from a porous member. The extraction element 1920 may also include one or more electrodes configured to 40 produce an electrical field across the filter media. Thus, the combination of the filter media and the electrical field causes separation of the highly charged DNA (identified by reference character DNA) from the other portions of the biological sample. Moreover, the extraction element 1920 can be con- 45 figured to separate DNA 1912 from other nucleic acids (i.e., RNA).

In some embodiments, the electrodes can be controlled to tailor the characteristics of the electric field, thus optimizing the separation characteristics of the extraction element. For 50 example, the electrodes can be controlled to adjust the strength, polarity, spatial variability and/or transient characteristics of the electric field. In some embodiments, the extraction element 1920 can include two electrodes: the first being disposed under the porous filter media, and the second 55 being disposed above and diagonally from the first.

As shown in FIG. 19, the library construction system may include a DNA fragmentation and/or size selection element 1916. The fragmentation and/or size selection element 1916 can be configured to produce double-stranded DNA fragments having blunted ends via the elements and methods described below. The fragmentation element 1920 includes one or more microfluidic channels 1922 within which the separated DNA may be disposed along with a set of fragmentation beads 1924. More particularly, the separated DNA 65 produced by the DNA extraction system can be conveyed or "injected" into the DNA fragmentation and/or size selection

24

element 1916 by any suitable mechanism (e.g., pressurized injection, electrophoretic movement, gravity feed, heat-induced movement, ultrasonic movement and/or the like). Similarly, the fragmentation beads 1924 can be conveyed into the DNA fragmentation and/or size selection element 1916 by any suitable mechanism.

The fragmentation and/or size selection element 1916 may include a pump 1926 to produce movement of the solution of DNA and fragmentation beads 1924 within the microfluidic channel 1922. The pump 1926 can be, for example, a peristaltic pump. In some embodiments, the pump 1926 can include one or more microfluidic elements in fluid communication with the microfluidic channel 1922, and having a flexible side-wall that, when deformed, produces a flow within the microfluidic channel 1922. In other embodiments, however, any suitable mechanism can be used to produce movement of the solution of DNA and fragmentation beads 1924 within the microfluidic channel 1922 (e.g., via selective heating and cooling of the solution, pneumatic pressurization of the microfluidic channel, electrophoretic motion, or the like.)

The fragmentation beads 1924 can be constructed from any material suitable for separating, cutting and/or otherwise dividing the DNA into DNA fragments (identified by reference character DNA-SEG). In some embodiments, the fragmentation beads 1924 can be constructed from glass, polydimethylsiloxane (PDMS), ceramic or the like. Moreover, the fragmentation beads 1924 can have any suitable size and/or geometry such that the fragmentation element 1920 produces DNA fragments having the desired characteristics (e.g., length, strand characteristics or the like). Moreover, the size and/or geometry of the microfluidic channel 1922 (e.g., crosssectional shape, aspect ratio or the like) can be selected such that the movement of the DNA within the microfluidic channel 1922 and in contact with the fragmentation beads 1924 produces the desired shearing of the DNA. For example, in some embodiments, the fragmentation beads 1924 can be substantially spherical and can have a diameter of 50 µm or less. In other embodiments, the fragmentation beads 1924 can have a diameter of 500 nm or less, or any diameter between 50 μm and 500 nm. In some embodiments, the microfluidic channel 1922 may be in the range of 1 to 500 µm in hydraulic diameter (i.e., as shown in FIG. 24, the cross-sectional area of the microfluidic channel 1922 can be substantially rectangular, thus the size can be represented as a hydraulic diameter). In other embodiments, the hydraulic diameter of the microfluidic channel 1922 can be in the range of 10 to 200 um. In yet other embodiments, the hydraulic diameter of the microfluidic channel 1922 can be in the range of 500 nm or less. Moreover, although shown in FIG. 24 as being substantially rectangular, in other embodiments the microfluidic channel can have any suitable shape, such as semi-circular, oval, tapered or the like. In some embodiments enzymatic polishing of the sheared DNA ends can be done to insure the ends are blunt ends.

In other embodiments, an enzymatic solution can be conveyed into the microfluidic channel **1922** to, at least partially, produce enzymatic fragmentation of the DNA.

Upon completion of the fragmentation, the DNA fragments may be separated from the fragmentation beads 1924. The DNA fragments can be separated from the fragmentation beads 1924 by any suitable mechanism, such as, for example, by a filter, by gravitational (or centripetal) separation, by an electrical field, or the like. In some embodiments, for example, the DNA fragments can be separated from the fragmentation beads 1924 by the actuation of one or more control lines or control channels, as described below with reference

to FIG. 20. In particular, the control channels may be channels that are fluidically isolated from, but adjacent and usually perpendicular to the microfluidic channel 1922. The control channels can, for example, be defined by a side wall that also defines a portion of the microfluidic channel. In this manner, 5 when the pressure of a fluid within the control channel may be increased, the common side wall can deform, thereby changing the flow area of a portion of the microfluidic channel **1922**. To separate the DNA fragments from the fragmentation beads 1924, a pressure can be selectively applied to the control channel such that the flow area of the microfluidic channel may be small enough to retain the fragmentation beads, but large enough to allow the DNA fragments to pass therethrough. Said another way, in some embodiments, the valves in the channel can be partially closed creating a leaky "sieve 15 valve" to separate the DNA fragments from the fragmentation beads 1924.

In some embodiments, the fragmentation and/or size selection element may comprise an electrophoretic device which may further comprise a set of electrodes embedded in a 20 microfluidic channel and may further include a means for introducing an entangled polymer, buffers and wash solutions.

As further shown in FIG. 19, the DNA fragments may then be conveyed into the amplification and enrichment systems. 25 The amplification and enrichment systems can be configured to produce clonally amplified DNA from the fragmented DNA that can be sequenced as described below. The PCR and enrichment system may include an array of microfluidic channels 1932 within which the DNA fragments may be 30 associated with a series of magnetic beads 1934. The DNA fragments and magnetic or paramagnetic beads 1934 may be positioned within the microfluidic channels via a corresponding magnetic array. In this manner, the DNA fragments and magnetic or paramagnetic beads 1934 can be maintained in 35 the desired position to promote accurate and efficient sample amplification. For example, the DNA fragments and magnetic or paramagnetic beads 1934 can be maintained in the desired position within the "flow-through" microfluidic channels 1932, and the desired reagents can be conveyed within 40 the microfluidic channels 1932 and into contact with the DNA fragments to promote amplification of the DNA fragments.

After amplification of the target DNA onto beads, the beads may be sorted in an electrophoretic sorter **1938** as previously described, and beads with appropriate amounts of amplified 45 product **1940** may be moved into a sequencing module **1936**.

As described above, the integrated sequencing platform can include all of the systems described herein within a single microfluidic/microelectronic device (or "chip") or may be modular devices in one system. FIGS. 20-24 show embodiments of the microfluidic portions of the integrated platform for extracting, amplifying and sequencing polynucleotides.

As in FIG. 20, a microfluidic device 2000 may have one or more input or output ports 2006. Fluids may be introduced through said ports 2006 to fluidic channels 2004. Control 55 lines 2002 may control the flow of fluids through the activation of valves 2008. Pressurizing the control lines 2002, deforms a wall between the control lines 2002 and the fluidic channels 2004, pinching off the fluidic channel and closing the valve 2008. FIG. 21 shows a further embodiment of the 60 fluidics system, with similar control lines 2102, fluidic channels 2104 and valves 2108, but with additional crossovers 2110, wherein the control line is narrowed too much to be able to fully deform to the point wherein the fluidic channel 2102 is sealed, preventing the crossover 2110 from acting as a valve 65 2108. FIG. 22 shows microphotographs of a portion of a device 2200A and 2200 B with enlarged fluidic channels

26

2204, permitting visualization of the activation of control line 2202. If the view of the device 2200A, the control line is not activated, and the valve 2208 can be seen to be open. After activation of the control line 2202, one can see that in device 2200B that the valve 2208B has deformed and sealed the fluidic channel 2204. FIG. 23 shows several views of a PDMS valving device 2302, including photomicrographs of paramagnetic beads 2304 in a channel, and view with a wherein flow is occurring, and where a valve has been activated and no flow occurs. The microfluidic device can control the "injection" or flow of the beads, reagents and/or samples described herein by a series of control lines that intersect with and/or impede upon the microfluidic channels described herein. As shown in FIG. 24 and described above, the control lines can be expanded to retain the solution and/or beads within a predetermined portion of the device.

For injecting picoliter amounts of amplification or sequencing reagents into the fluidic system, e.g., for incorporation of dNTPs onto bead-immobilized DNA primers, the magnetic array may utilize a micro-fluidics system. For example, the microfluidic platform may contain lines for injecting/delivering reactants to the localized magnetic fields. For sequencing embodiments, the microfluidic system controls sequential injections of nucleotide triphosphates to the substrate or to localized magnetic fields. The microfluidic channels may be in the range of 1 to 100 μ m in diameter, or in certain embodiments, in the range of 10 to 20 μ m in diameter. Materials and methods for fabricating the micro-fluidics system are known. For example, the microfluidics system may be fabricated with polydimethyl siloxane (PDMS), molded or machined plastic or glass.

The invention therefore provides in certain aspects, a magnetic array, as described herein, having a magnetic bead or particle trapped by magnetic force at a plurality of the localized magnetic features, each magnetic bead or particle having bound thereto a clonally amplified DNA segment for sequence analysis. The DNA segment may be clonally amplified, for example, using the magnetic array, optionally having an electric field, as described herein.

The amplification and sequencing arrays may be placed in sequential order in an integrated platform. For example, after amplification on a magnetic array, the beads may be enriched based on a DNA electrophoretic force. Specifically, the beads with amplified DNA, and with the adequate length, may have the minimum required charge to be pulled off to an exit integrated with a DNA sequencer. The null beads, as well as beads with incomplete amplification or overly short DNA amplicons, may be separated through another outlet.

It may be desirable to process multiple samples in a single chip, since many projects do not require the full capacity of a chip. Other projects may have a single sample that would exceed the capacity of the chip. In some embodiments one or more samples could be introduced into the instrument in individual tubes, tube strips, 96-well plates, 384-well plates, etc. In some embodiments the sample wells could be sealed to prolong life on the instrument. In other embodiments the plates may be cooled to increase sample life. In other embodiments the samples could be accessed in a software selectable manner by a robotic pipettor. The system could divide the samples over multiple fluidic channels or chips if they are too large, or combine the samples if they are combinable (for example using sequence barcoded samples). In some embodiments sample may be loaded at different times in the same sequencing device in different channels, enabling samples to be run when they become available. In some embodiments samples provided to the instrument would be ready for

sequencing. In other embodiments samples could be processed by the instrument to generate sequencing ready samples.

In one embodiment a target concentration may be created by a hybridization based pullout. A solid support such as 5 pull-out beads could be functionalized with a controlled number of binding sites. In some embodiments these could be DNA primer compliments. The unamplified sample may have known primers ligated on each end. In some embodiments the primers would hybridize to the DNA on the pull-out beads. 10 After the sites are exhausted, residual DNA would be washed away, and the DNA bound to the beads would subsequently be denatured releasing a known quantity of DNA.

In another embodiment the primers ligated to each DNA fragment could be bound to the primer compliment and 15 detected using fluorescence detection of an intercalating dye. Since the primers may be of a known length, the signal level may be proportional to the number of fragments. In another embodiment polymerase and associated dNTPs could be introduced creating full length double stranded DNA. When 20 combined with the information from the primer signal the full length intercalating dye signal level would then allow determination of the mean fragment length.

Although various embodiments have been described as having particular features and/or combinations of components, other embodiments are possible having a combination of any features and/or components from any of embodiments as discussed above.

While various embodiments have been described above, it should be understood that they have been presented by way of a example only, and not limitation. Where methods and/or schematics described above indicate certain events and/or flow patterns occurring in certain order, the ordering of certain events and/or flow patterns may be modified. While the embodiments have been particularly shown and described, it will be understood that various changes in form and details may be made. While the embodiments have been particularly shown and described for nucleic acid detection or DNA sequencing, it will be understood that the system may be configured or used for various other biochemical reactions and detection thereof.

What is claimed is:

- 1. A method for sequencing, comprising:
- (a) providing a plurality of particles, wherein each particle of said plurality is coupled to on average at most one nucleic acid molecule;
- (b) performing simultaneous nucleic acid amplification reactions on said nucleic acid molecules coupled to said particles, wherein said nucleic acid amplification reactions are performed while subjecting the particles to an electric field, thereby producing isolated, clonally-amplified nucleic acid molecules coupled to said plurality of particles;
- (c) performing nucleic acid extension reactions on said clonally-amplified nucleic acid molecules using primers that hybridize to said clonally-amplified nucleic acid molecules; and
- (d) detecting nucleic acid incorporation events from said extension reactions using a sensor array to determine a sequence of each of said clonally-amplified nucleic acid molecules, wherein each particle of said plurality of particles is adjacent to a sensor of said sensor array, and wherein each said sensor of said sensor array comprises two electrodes that are within a Debye length of their

28

- respective individual particle or within a Debye length of a nucleic acid molecule on said individual particle.
- 2. The method of claim 1, wherein said nucleic acid amplification reactions are emulsion free.
- 3. The method of claim 1, further comprising, subsequent to (b), separating particles carrying clonally-amplified nucleic acid molecules from particles not carrying clonally-amplified nucleic acid molecules.
- **4**. The method of claim **1**, wherein (b) is performed with the plurality of particles held adjacent to the sensor array.
- 5. The method of claim 1, wherein, in (c), the particles are at least one of electrically and magnetically immobilized.
- **6**. The method of claim **1**, further comprising releasing one or more of said plurality of particles.
- 7. The method of claim 1, wherein, in (d), detecting said nucleic acid incorporation events further comprises using an individual sensor among the plurality of sensors to detect at least one of local impedance change and local conductivity change.
- **8**. The method of claim **1**, wherein the electric field isolates or concentrates one or more of template DNA fragments, primers, polymerase, and dNTPs around each of the particles.
- 9. The method of claim 1, wherein the electric field isolates or concentrates products of nucleic acid amplification reactions.
 - 10. A method for nucleic acid sequencing, comprising:
 - (a) directing a plurality of particles onto an array of sensors, wherein an individual particle comprises a nucleic acid molecule, and wherein an individual sensor of said array comprises a pair of electrodes that are electrically coupled to a Debye length of said individual particle during nucleic acid sequencing;
 - (b) positioning said individual particle at said individual sensor;
 - (c) directing a plurality of primers onto said array;
 - (d) performing a primer extension reaction at said individual sensor; and
 - (e) during or subsequent to performing said primer extension reaction, measuring a change in impedance of said individual particle with the aid of said pair of electrodes that are each electrically coupled to said Debye length of said individual particle.
- 11. The method of claim 10, further comprising amplifying said nucleic acid molecule prior to (d).
- 12. The method of claim 11, wherein said nucleic acid molecule is amplified while subjecting said individual particle to an electric field.
 - 13. The method of claim 11, wherein said nucleic acid molecule is amplified while said individual particle is held at said given sensor.
 - **14**. The method of claim **1**, wherein an individual electrode of said two electrodes has a Debye length.
 - 15. The method of claim 14, wherein said Debye length of said individual electrode is within said Debye length of said individual particle or said Debye length of said nucleic acid molecule on said individual particle.
 - 16. The method of claim 10, wherein, in (e), the electrodes of said pair of electrodes are within said Debye length of said individual particle.
 - 17. The method of claim 16, wherein an individual electrode of said pair of electrodes has a Debye length.
 - **18**. The method of claim **17**, wherein said Debye length of said individual electrode is within said Debye length of said individual particle.

* * * * *